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ABSTRACT
Considerable evidence has demonstrated the importance of basolateral amygdala
(BLA) in associative learning and memory processing. Furthermore, recent evidence at
the behavioural and molecular levels, implicates an important role for the BLA in the
processing of drug-related learning and memory events. Through anatomical connections
with the mesolimbic dopamine (DA) system, neuronal activity and plasticity within the
BLA are altered through DA receptor transmission originating in the ventral tegmental
area (VTA). However, the specific function of DA receptors within the BLA during
associative opiate reward learning is not clear. We used a place preference conditioning
paradigm and pharmacological manipulations of DA D1 and D2 receptors to examine the
role of DA Dl-like versus D2-like receptors within the BLA, as well as the downstream
secondary messenger cAMP during associative opiate reward memory encoding in both
opiate-naive and opiate-dependent rats. We report that blockade of DA D1 receptors
within the BLA disrupts the acquisition of associative reward memory in opiate-naive
state, whereas DA D2 receptor blockade does so in the opiate-dependent state.
Furthermore, DA D1 receptor activation potentiates the rewarding effects of morphine in
the opiate-naive state, while DA D2 receptors activation exerts the same action in the
opiate-dependent state. Finally, pharmacological manipulation of cAMP levels in the
BLA is not only able to mimic the behavioural effects of DA receptor blockade or
activation, but also reverses the effect of both DA receptor agonists and antagonists,
regardless of opiate exposure state. These results indicate that depending on the opiate
exposure state, DA D1 versus D2 receptors within the BLA play differential roles in

in

modulating the encoding of associative opiate reward memory through a cAMP
dependent mechanism.

Keywords: Basolateral amygdala, Opiate, Dopamine, Dopamine receptors, Associative
Learning, Conditioned Place Preference, cAMP, Reward
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Chapter 1 Introduction
Drug addiction is a pathological condition resulting from repeated consumption of
a drug, either natural or synthetic. The disorder of addiction entails a transition from
initial drug use to the emergence of compulsive drug-seeking and drug-taking behaviour,
as well as diminished response to natural rewards, such as food. It is widely accepted that
the underlying cause of such maladaptive behaviour is drug-induced changes in structure
and function of a brain circuit, which is responsible for processing reward, motivation
and associative learning (Kalivas, 2002; Koob, 2009). The search for the underlying
neurobiological basis of addiction has revealed that drugs of abuse are capable of
establishing neuroplastic changes in neurons, and therefore alter the connectivity of brain
reward circuitry (Feltenstein and See, 2008). Opiate class drugs, such as morphine and
heroin, represent highly addictive drugs of abuse due to their profound euphorigenic and
pain-relieving properties upon acute exposure. However, sustained consumption of
opiates leads to rapid physical and psychological dependence, characterized by a severe
psychological and physiological withdrawal syndrome, compulsive drug seeking and
chronic relapse (renewed drug-taking after a period of abstinence). Moreover, the highly
addictive properties of opiates can serve as powerful reward cues for associative learning
and memory processes, through which environmental cues become linked to opiate
reward and the opiate-using experience (Self and Nestler, 1998; Stewart 2008). The
formation of such learned associations resulting from repeated opiate use poses great risk
for relapse and tremendous difficulties in addiction treatment.
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Given the detrimental social and economical impact of drug addiction, vast
amount of research has been conducted to address the neuropharmacologoical
mechanisms underlying the progressive development of addictive behaviours and the
vulnerability to relapse, yet many questions remain unanswered. When opiate users shift
from a naive state to a dependent and withdrawn state, what precise neuroadaptive
alterations take place in parallel with the progression and expression of addictive
behaviour? If opiates affect the functionality of a specific network in the brain, how does
opiate exposure alter the way one particular component of the circuit interacts with the
others, and what cellular signalling pathway might mediate such alterations? This thesis
will discuss and attempt to address these questions with an emphasis on a circumscribed
brain reward circuit, the mesocorticolimbic system, comprising the ventral tegmental area
(VTA), nucleus accumbens (NAcc) and the functional interactions of this system with the
basolateral nucleus of the amygdala (BLA). As will be described in detail shortly, these
three regions are all involved critically in the processing of opiate reward related
motivational signalling (Frenois et al., 2005; Tzschentke and Schmidt, 1999; Wise 1989)
and are each functionally interconnected. Specifically, my project has focused upon the
role of the neurotransmitter dopamine (DA) and its modulatory role in the encoding of
associative opiate reward memory during distinct phases of the opiate addiction cycle: the
early, acute phase of opiate exposure, versus the later, chronically dependent and
withdrawn stage of opiate exposure. Furthermore, my research project takes a special
interest in functional dopamine (DA) transmission from the VTA to the BLA, and the
effects of DAergic transmission along this VTA to BLA projection on the encoding of
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associative opiate-related memory via D1 and D2 receptor subtype populations within the
BLA.

Using a simple, Pavlovian associative learning procedure in rats (conditioned
place preference, CPP), my results demonstrate that the functional role(s) of DA D1
versus D2 receptor transmission specifically within the BLA, are switched as a function
of opiate exposure state: while transmission via intra-BLA DA D1 receptors are critically
involved in opiate reward processing during ‘acute’ opiate exposure, once animals
become dependent on opiates and are in a state of opiate withdrawal, the functional role
of intra-BLA DA transmission switches to a DA D2 receptor population. Thus, my
findings demonstrate a functional double dissociation of DA D1 versus D2 receptor
transmission within the BLA as a function of opiate exposure state. These results
characterize a novel DA receptor-dependent ‘opiate addiction switching mechanism’
directly within the mammalian BLA, which appears to directly control how VTA-BLA
DA transmission regulates the encoding of associative opiate reward information as a
function of opiate exposure state. I further demonstrate a critical role for the downstream
secondary messenger cyclic AMP (cAMP) activity, as an underlying molecular
mechanism for this DA-mediated switching mechanism. Finally, our work reveals that
modulation of opiate reward related associative memories are critically dependent upon
functional outputs from the BLA to the NAcc.

1.1 Opiates and How They Work
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Opium, processed from poppy plants gives rise to a category of alkaloids
collectively named opiates. The major active constituent as well as the most abundant one
is morphine, and the common derivatives o f the constituents are heroin, oxycodone, and
hydrocodone. Opiate-class drugs exert the physiological effect by acting on three types of
opioid receptors expressed throughout the brain, mu (p), delta (8) and kappa (k ). Opioid
receptors belong to a G protein-couple receptor (GPCR) family with opioids as their
substrates. The human body produces many natural endogenous opioid peptides, for
example, dynorphins, endorphins, endomorphins, etc. Within the central nervous system
(CNS), opiates are capable of mimicking the action of endogenous opioids, and therefore
producing pain-relieving effect and an intense state of euphoria. In the context of my
studies, morphine and its derivative ‘heroin’ are the two types of opiate-class drugs under
investigation. Although morphine is able to bind to all three opioid receptors, it
predominantly binds to mu (p)-opioid receptors and blockade of mu (p)-opioid receptors
attenuates opiate self-administration (Negus et al., 1993). It is through the action of these
receptors that opiates alter the neuronal plasticity of the endogenous opioid system and
participate in the development of opiate dependence (Nestler et al., 1993). Among
numerous mu (p)-opioid receptor binding sites in the brain, high intensity binding
appears in a few discrete cortical regions, such as thalamus, ventral tegmental area (VTA),
and Nucleus Accumbens (NAcc) (DeVries and Shippenberg, 2002).

In the presence of opiates, the VTA sends DAergic projections to various brain
regions in the mesocortical and mesolimbic dopamine pathway, such as the prefrontal
cortex (PFC), amygdala and the NAcc, and these three DA projections have been
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frequently evaluated. DA transmission between VTA and PFC has been implicated for its
role in higher order cognitive functions such as executive function and emotional
response (Volkow et al., 2009). Also, DA projections from the VTA are thought to
modulate the neuronal activities of the NAcc and serve as key neural substrates for the
reinforcement of drug-seeking behaviour in morphine addiction (Ma et al., 2009). The
VTA and the NAcc are also two components of the mesocorticolimbic DA system, which
has been extensively studied in the context of addiction for its association with reward
and incentive motivation. The ‘A10’ DA neuronal bodies localized within the VTA
provide the major DA input within the mesolimbic system, and it is widely accepted that
opiates act on mu (p) - opioid receptors in the VTA and increase the firing rate of DA
cell bodies (Wise 1996, Svingos et al., 2001). The functional arrangement of VTA
neurons and how opiates modulate the VTA DA output will be discussed later in this
chapter.

Considerable evidence suggests that the DA pathway plays a critical role in the
rewarding properties of opiate-class drugs. Antagonist and neurotoxic lesion studies have
revealed that blockade of the mesolimbic DA pathway is able to attenuate the rewarding
effect of opiates (Bozarth and Wise, 1981; Leone and Di Chiara, 1987). However, other
evidence suggests that the role of DA transmission in the processing of opiate-related
reward information is critically dependent upon the state of opiate exposure (Bechara and
van der Kooy, 1992). For example, Laviolette et al. (2002; 2004) reported that within the
mesolimbic system, opiate reward signaling switches from a DA-independent reward
pathway (mediated via descending projections to the pedunculopontine nucleus in the
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brainstem) in the acute, non-dependent phase of opiate exposure, to a DA-dependent
opiate reward pathway once the animal becomes dependent on opiates and is conditioned
in a state of opiate withdrawal. In other words, the VTA serves as a central ‘opiate
addiction switching’ centre between a non-DA reward pathway and a DA-dependent
system. However, while these studies focused on DA dependent and independent neural
systems that are responsible for the processing of the primary rewarding effects of opiates,
little is known about how DA transmission is altered in neural sites extrinsic to the VTA
as a function of opiate exposure state, nor how these neuroplastic changes may influence
the encoding of associative learning and memory related to the opiate addiction. Thus,
how do changes in DA transmission originating in the VTA as a result of opiate exposure
modify other neural targets of the VTA DA system, particularly in the context of opiaterelated learning and memory? As will be described shortly, the primary goal of my
studies is to determine the potential role of the BLA, a neural region critical for
associative reward learning and memory (LeDoux 2000; McGaugh, 2002) as one such
target. Importantly, the BLA also receives functional DA input from the VTA, which has
been reported to strongly modulate neural mechanisms related to learning and memory
related plasticity (Bissiere et al., 2003).

1.2 Opiate Addiction and Associative Learning
As with many forms of addiction, opiate dependence is a chronically relapsing
disorder. Thus, opiate drug abusers will typically continue to compulsively seek out
opiates even after a period of long abstinence, regardless of the profound and disastrous
impact the addiction has caused, both physically and psychologically. Indeed, relapse is
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common among many drug addicts and presents a great challenge for addiction treatment.
One study done on heroin abusers showed that relapse could take place even after 15
years of abstinence (Martin et al., 2007). Many earlier studies on the neurobiology of
addiction have focused on the acute effect of drug use and in the identification of neural
pathways responsible for mediating the acute euphorigenic effects of the particular drug.
However, the aims of addiction neuroscience have shifted somewhat to focus on the
effects of long-term drug administration and neuroadaptations in the brain that may
underlie drug-related memory and associative learning leading to drug-related relapse.
Drug-taking experiences form ‘associative’ drug-related memories, which can be
reactivated by context or specific ‘cues’ that have been associatively linked to drug
taking or drug withdrawal (Childress et al., 1993; Stewart 2008). Work done by O’Brien
et al. (1993) also demonstrated that exposure to environmental cues previously associated
with drug reward strongly increases the risk of relapse and such conditioned response can
occur despite years of abstinence. What happens at the neural level that mediates this
abnormal behaviour and compulsive desire to seek out drugs, long after the initial drug
taking experience? In the context of associative learning, repetitive drug use (leading to
an unconditioned response: high or euphoria) typically becomes linked to specific
environmental cues (a conditioned stimulus or CS+). Overtime, according to basic
Pavlovian conditioning principles, such cues (CS+) will acquire the ability to evoke
associative memories and behaviours previously linked to the drug taking experience
(UR). Thus, re-exposure to drug-related cues have the ability to activate neural
associative learning circuits engaged in drug use, and re-exposure to these stimuli is able
to evoke drug craving and reinstate drug-seeking behaviour in both humans and animals
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(Self and Nestler, 1998; Koob and Le Moal, 2001). Therefore, when paired with opiate
reward, environmental cues predicting the availability of opiate act as critical neural
substrates involved in drug-seeking behaviour.

The pairing between drug reward and environment cues is a form of Pavlovian
associative learning and memory. In terms of how the brain encodes such associative
information, considerable evidence converges on a network of brain areas that receives
DA input, for example NAcc, PFC and amygdala (Ambroggi et al., 2008; Tzschentke and
Schimdt, 2000; Kalivas and Nakamura, 1999). These neural regions appear to play a
critical role in processing the motivational significance of incoming sensory information
and in the motivational value of such experiences (Heyman et al., 2006). As mentioned
previously, these same neural regions have also been implicated in drug addiction,
meaning that associative memory processing and addiction-related learning may share the
same brain circuitry and that drugs of abuse can be viewed as powerful memory
modulators (White, 1996; Fuchs et al., 2000; Nestler, 2002). With repeated drug
consumption, the brain is thus capable of learning the predictive value of environmental
cues (CS+) and linking the associative memory to certain behavioural response, such as
seeking drugs. Therefore, it is reasonable to postulate that disruption of drug-related
associative learning processes may be able to diminish the impact of drug-related
associative cues and increase the success rate of addiction cessation by modulating the
impact of drug-related learning and memory processes that can lead to cue-induced
relapse to drug seeking behaviours.
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Given the memory-modulating properties of opiate-class drugs and the associative
learning ability of the brain, a variety of animal models are created for understanding the
neurobiology of addiction and the neuropharmacologoical action of opiates. For example,
animals can be trained to intravenously self-administer a wide variety of drugs of abuse.
While this procedure has the advantage of looking at voluntary drug self-administration,
it has the disadvantage of being technically difficult and requires many weeks of training.
Animals are typically tested with the drug-on-board system, which may in and of itself
confound results by producing non-specific motor side-effects. The other predominant
behavioural paradigm to examine drug-related behaviours is the conditioned place
preference (CPP) model.

The CPP paradigm uses the principle of Pavlovian classical conditioning and
detailed experimental procedures will be discussed in Chapter 2 (Materials and Methods).
According to this principle, if a drug with reinforcing properties is given, animals should
be able to establish associative memory formation explicitly pairing the environmental
stimuli (conditioned cues) with drug reward and therefore demonstrate a place preference
for drug-paired environment. A major advantage to the CPP procedure is that animals are
tested in a ‘drug-free’ state, thus the dependent variable of the test relies exclusively on
previously acquired associative memories related to the prior conditioning procedures.
Motor confounds produced by the drug itself are thus not an issue during the actual
testing procedure. The CPP procedure has the additional advantage in that animals will
form conditioned place aversions (CPA) to environments linked to unpleasant
experiences, such as opiate withdrawal. It has been reported that many drugs of abuse
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including opiates can induce a conditioned place preference (CPP) in animals (Swerdlow
et al., 1989). The CPP paradigm is proven to be a quick and useful way to access the
behavioural response of animals under opiate influence as well as the effect of intra
cranial pharmacological manipulations.

1.3 Brain Areas Involved in Opiate-related Associative Learning and
Memory
As discussed previously, it is apparent that the process of associative learning and
memory formation plays a crucial role in the opiate addiction process. In order to
understand the neural basis of opiate addiction, it is important to know which brain
regions are involved in this process and what neuroplastic changes they undergo as a
result of opiate exposure. As reviewed above, early research focused on mesolimbic DA
projections from the VTA to the NAcc as critical mediators of the acute, euphoric effects
of opiates (Frenois et al., 2005, Wise 1989, 1998). However, as will now be reviewed,
recent research regarding learning and memory related processes underlying opiate
addiction have increasingly focused on the importance of neural regions like the PFC and
amygdala, as critical neural substrates involved in associative opiate-related learning and
memory.

1.3.1 The Effects of Opiates on Neuronal Activity within the VTA
As mentioned previously, the behavioural and physiological cascade of opiateclass drugs starts by binding to opioid receptors and the binding to mu (p)-opioid
receptors is especially important for morphine and heroin reward (DeVries et al., 2002).
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The VTA, as one of several high density p-opioid receptor binding sites, is believed to be
an area where primary morphine reinforcement takes place (McBride et al., 1999;
Laviolette et al., 2004). Blockade of mu (p)-opioid receptors in the VTA attenuates
heroin self-administration and CPP response associated with morphine administration
(Shippenberg and Elmer, 1998). From a functional perspective, there are two sizeable
neuronal populations in the VTA: DA projection neurons and intrinsic GABAergic
intemeurons that regulate the activity of the DAergic neurons. Most, if not all of the mu
(p)-opioid receptors are localized exclusively on the GABA axon terminals and cell
bodies as opposed to the DA neurons (Garzon and Pickel, 2001). These VTA GABA
intemeurons synapse on DAergic neurons and inhibit their neuronal activities (Svingos et
al., 2001).

As shown in Figure 1, opiate-class drugs stimulates mu (p)-opioid receptors on
GABA intemeurons and inhibits the release of GABA, thereby removing the inhibitory
effect on DAergic neurons and increasing their firing activities (Wise 1996; Kalivas
2002). Through the action of these intemeurons, opiates indirectly enhance VTA DA
output to numerous brain areas with mesolimbic and mesocortical DA pathways as the
two primary targets. Figure 1 is a simplified model demonstrating this GABA neuron
mediated modulation of VTA DA output. In actuality, almost all brain structures
receiving DA inputs have recurrent projections back to the VTA, making the functional
interrelationships between the VTA DA projections and target areas highly complex and
not entirely characterized. Nevertheless, for the scope of this thesis, the DA projection
from VTA to the BLA is our main focus of experimental inquiry.
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Figure 1
Opiates modulation of the dopamine output from VTA to BLA

There are two sizable neural populations within the VTA and they are the DA projection
neurons and the GABA intemeurons that modulate the DA release. Opiate class drugs act
upon p-opioid receptor residing on GABAergic intemeurons, and subsequently remove
the inhibitory effect on DAergic neurons, which in turn amplifies DA outputs to the BLA.

13

Opiates
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1.3.2 Basolateral Amygdala: Role in Emotional Learning, Memory and OpiateRelated Behaviours
The amygdala has long been known for its role in emotional processing such as
fear, anxiety, and negative emotional behaviour during morphine abstinence as well as
positive emotions and learning (Baxter and Murray, 2002; Hand et al., 1988; LeDoux
2000). In primates, amygdala lesions attenuate appetitive responses to food-related
conditioned stimuli, indicating the importance of amygdala in reward processing and
associative learning processes (Braesicke et al., 2005). Interestingly however, the BLA
itself is not implicated in the primary rewarding effects of opiates. For example,
microinfusions of morphine directly into the amygdala fail to produce any reinforcing
effects, as measured in a CPP procedure in rats (Olmstead and Franklin, 1997).

Anatomically, the amygdala has several subnuclei including the central nucleus
(CeA) and the basolateral nucleus (BLA), and studies have indicated a flow of associative
conditioning information from the BLA to CeA (LeDoux 2000; Phillips et al., 2003).
Excitotoxic lesions of CeA impair the acquisition and expression of approach to food
reward; whereas lesions in BLA prevent neutral environmental stimuli from being
associated with reinforcing outcomes, such as food and sex (Robbins et al., 2008), which
suggests that while the CeA plays more of a general motivational role, the BLA encodes
specific sensory features of the reinforcers and contributes to the formation of associative
reward memory and goal-directed behaviour (Baxter and Murray, 2002). A review
written by Ballerin and Killcross (2006) has also gathered additional evidence to support
this notion. It is not surprising that the BLA might contribute to the formation of opiate-
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related associative learning. Although more evidence suggests that the BLA plays a role
in incentive behaviours, it is still a topic under debate. In our lab, we are more interested
in examining the “encoding” ability of BLA in the context of opiate associative reward
memory.

The BLA receives afferent inputs from many sources in the brain directly or
indirectly, especially areas that are responsible for sensory information processing; for
example, BLA receives dense projections from thalamus, auditory, somatosensory and
visual cortex (Phillips et al., 2003). This is consistent with evidence demonstrating that
the BLA plays a critical role in establishing associations between sensory stimuli and
events that present motivational and emotional salience (LeDoux 2000; McGaugh 2002).
The BLA also has reciprocal connections with the PFC and hippocampus, through which
the BLA modulates memory and cognitive processes (McGaugh 2002, 2004; McDonald
et al., 1996). The latter is supported by studies done by Winstanley and colleagues (2004)
and they showed that rats with BLA lesions exhibit poor decision-making and
increasingly impulsive actions, such as choosing small immediate rewards over delayed
large rewards, behaviours we often see in human addict.

In terms of opiate reward

learning, the actual function of the BLA is not fully understood. In one study using
morphine CPP procedure, researchers found that GABAa receptor agonist administered
into the BLA decreased the acquisition of CPP induced by morphine, whereas antagonist
produced a significant CPP for an ineffective dose of morphine, indicating the
involvement of BLA in morphine reward processing (Zarrindast et al., 2004). On the
other hand, Alderson et al (2009) showed that the integrity of the BLA is not essential for
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heroin self-administration and that the BLA is not critically involved in heroin-seeking
behaviour. Moreover, an important study by Frenois et al. (2005) revealed that BLA
neuronal population activation (as measured by c-fos immunohistochemistry) was
strongly correlated with the expression and acquisition of associative memories for
morphine-related associative learning (also measured in a CPP procedure), and also for
associative memories related to opiate withdrawal. Thus, considerable evidence both
behaviourally and at the molecular level implicates that the BLA in the encoding and
expression of associative opiate-related learning and memory. Nevertheless, the precise
role of the BLA in opiate-related learning and memory is not fully understood.

In addition to its connectivity with the mesolimbic system, the BLA receives
descending influences from the mPFC, consisting of glutamatergic terminals that induce
excitation of BLA inhibitory intemeurons under normal circumstances, and thus act as a
“braking” mechanism on the output of BLA projection neurons (Rosenkranz and Grace,
2002; Wan and Swerdlow, 1997; Fig. 2). At the network level, 85% of neurons within the
BLA are pyramidal neurons using glutamate (GLUT) as an excitatory neurotransmitter
(Millhouse and DeOlmos, 1983; Fuller et al., 1987) and most of the intrinsic inhibitory
inputs to these neurons are coming from local GABAergic intemeurons (Mariwsky et al.,
2005; Muller et al., 2006). Both types of neurons express DA receptors and can be
functionally modulated by DA input from the VTA (Rosenkranz and Grace, 1997; Kroner
et al., 2006). Actually, the BLA maintains reciprocal connections with many neural
regions including VTA, PFC and NAcc (McDonald 1991; Phillips et al., 2003), far more
complex than what it is shown in our simplified model (Fig. 2).
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Figure 2
VTA, BLA and mPFC interactions

In addition to the VTA DA input, mPFC also sends projections to the BLA via GLUT
transmission. Within the BLA, there are GABAergic intemeurons and pyramidal neurons.
Both types of neurons express DA receptors, and therefore can be modulated by VTA DA
input.

mPFC GLUT
input
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With respect to efferent projections from the BLA, it is noteworthy that the BLA
projects heavily to the NAcc primarily via excitatory glutamatergic projections, whose
connection with the VTA has been implicated in opiate reward processing (Koob 1992;
Floresco et al., 1999). Considering the above mentioned behavioural, anatomical and
functional relationships between the BLA, VTA and NAcc, it is very likely that the BLA
plays a critical role in associative opiate reward learning and memory processes.

1.3.3 Nucleus Accumbens
The NAcc is a major component of ventral striatum and mesolimbic system with
major inputs coming from PFC, BLA and VTA (Berendse, 1991). While the amygdala
plays a role in conditioned learning (See, 2002), the NAcc is more likely engaged in
mediating the primary reinforcing properties of drugs of abuse (Di Chiara, 2002). The
NAcc has been characterized as a “limbic-motor” interface responsible for coordinating
motor/behavioural responses to limbic input (Ambroggi et al., 2008; Mogenson et al.,
1980). Due to its anatomical position between limbic structures such as the VTA and
amygdala, it is essentially a motivational output/expression centre with motor output
circuits such as its projections to brainstem mesencephalic regions via the ventral
pallidum (Mogenson and Nielsen, 1983; 1984). The NAcc receives dense DA projections
from the VTA and microdialysis studies show that almost all drugs of abuse increase
extracellular concentrations of DA in the NAcc. When DA receptor antagonists are
administered into the NAcc, morphine reward is blocked in opiate-withdrawn rats
(Laviolette et al., 2001). Like the VTA, the NAcc also expresses a high density of mu
(p)-opioid receptors and opioids have been reported to be self-administered into the
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NAcc (Koob and Volkow, 2010). Besides the VTA, studies have shown that the
connection between the BLA and NAcc is critically involved in goal-directed behaviour
in response to reward-predictive cues (Ambroggi et al., 2008, Floresco et al., 1999;
Johnson et al., 1994). Neurons in NAcc not only encode the values of predictive cues
(Hassani et al., 2001) also the action response leading to the reward (Nicola et al., 2004;
Nicola 2007). Prolonged drug use induces long-lasting neuroadaptations that result in
changes in neural circuitry organization and considerable evidence indicates that after
exposure to addictive drugs, plastic neuronal alterations takes place in the NAcc in
various ways, including altered neurotransmitter release, neuronal excitability and in
terms of cellular morphology (Jacobs et al., 2005).

Both anatomically and functionally, the NAcc can be subdivided into core and
shell regions, each with specific patterns of inputs and outputs to limbic and motor
regions. Several studies have shown that addictive drugs such as morphine preferentially
increase dialysate DA in the shell rather than the core (Di Chiara and Bassareo, 2007;
Pontieti et al., 1995). While both are involved in motivational behaviour and addiction,
DA transmission in the shell seems abnormally strengthens stimulus-drug association,
indicating a role in incentive learning; whereas the core is more consistent with a role in
expression of motivation (Di chiara, 2002; Di Chiara et al., 2004). Self-administration
studies also points to the NAcc shell as the most sensitive site for DA-dependent reward
(McBride et al., 1999; Ikemoto et al., 1997). Perhaps most importantly, anatomical
evidence suggests that the BLA sends stronger glutamatergic projections to the shell as
opposed to the core subdivisions (McDonald 1991a), suggesting that BLA-NAcc shell
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connections may be relatively more important for the transmission of motivationally
salient associative information (encoded within the BLA) to motivational behavioural
output pathways within the NAcc shell.

Beyond the BLA and NAcc, another important neural region sending functional
projections to both BLA and NAcc is also implicated in drug reward learning and
memory processing, and that is the prefrontal cortex (PFC).

1.3.4 Prefrontal Cortex
The PFC has been implicated in complex planning, decision making and higher
order of executive functions (Kennerley et al., 2006). As part of mesocorticolimbic
dopamine system, it receives prominent DA inputs from the VTA and sends
glutamatergic projections to the NAcc. It is believed that the PFC is well situated to
modulate the activity of the DA pathway while simultaneously being influenced by it via
recurrent feedback (Tzschentke, 2000). Besides the VTA and NAcc, PFC also receives
input from thalamus and amygdala and sends efferent projections to numerous motor and
limbic areas (Conde et al., 1995; Gabbott et al., 2005). Through these complex
interactions, PFC is critically involved in associative opiate reward learning and memory.
For example, experiments conducted by Hao et al. (2008) show that lesions to the PFC
blocks the acquisition of morphine CPP in mice. In addition, Tzschentke and Schmidt
(1999) have reported that excitotoxic lesions to distinct regions of the PFC can block
specific phases of associative opiate reward learning. Finally, our laboratory has recently
shown that pharmacologically induced hypofunction of NMDA receptor transmission via
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the BLA can dramatically potentiate the rewarding properties of opiate reward signalling
either systemically or directly in the VTA (Bishop et al., 2010).

Behavioural human imagining studies have found that the PFC plays a significant
role in the retrieval of morphine associated memories, indicating the PFC might be
involved in associative memory storage (Phillips et al., 2004; Sell et al, 1999, 2000).
Finally, since the PFC is implicated in higher order cognitive functions, changes in PFC
neuronal activities might contribute to the impulsive behaviour in heroin addicts (Bechara,
2005; Lee et al., 2005). Based on the existing evidence, it is apparent that the PFC is
significantly involved in opiate-related associative learning and memory processing.

1.3,5 Proposed Model for Opiate Associative Learning
I have thus far discussed four key brain regions (VTA, BLA, NAcc and PFC)
implicated in reward and motivation processing as well as their significance in the
context of drug reward learning and memory. Our proposed model of opiate associative
learning involves an interconnecting network of all four brain areas. In Figure 3, we
present a simplified model showing functional and anatomical relationships between the
BLA-mPFC-NAcc neural regions. We hypothesize that opiates produce their primary
rewarding effects through actions within the VTA involving GABAergic and DAergic
neuronal populations. Associative opiate reward information is transferred to the BLA via
DA transmission. Because the BLA also receives sensory information from thalamus and
other cortical regions, we proposed that the BLA combines two types of information and
pairs the environmental cues with opiate reward, initiating associative memory encoding
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Figure 3
This figure shows a simplified model demonstrating the functional and anatomical
relationships of the VTA-BLA-mPFC-NAcc neural circuitry. This model is based upon
the hypothesis that opiates produce the primary rewarding effects through actions within
the VTA involving GABAergic and DAergic neuronal populations. Associative opiate
reward information is transmitted to the BLA and eventually transferred to the PFC for
long term associative memory storage. We hypothesize that the expression (recall) of
associative opiate reward information (such as during the expression phase of opiaterelated associative learning and memory) involves an integrated network of NAcc
neurons receiving convergent DAergic and glutamatergic input from VTA, mPFC and
BLA.
1: Opiate motivational salience input to the BLA
2: Transmission of opiate associative memory for long term storage
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process. The BLA eventually delivers the processed information to the PFC for long-term
associative memory storage, as suggested by previously discussed research (Phillips et al.,
2004; Sell et al, 1999, 2000). Based on the role of NAcc as a limbic motor interface, we
propose that the expression (recall) of associative opiate reward information (such as
during the expression of opiate-related associative learning and memory within the CPP
paradigm) involves an integrated network of NAcc neurons receiving convergent input
from the three brain areas and generating appropriate behavioural/motor responding.
Although the VTA-NAcc interaction has been studied intensively, the relative roles of the
BLA and PFC inputs to the NAcc during the execution of opiate-related learning and
memory are not presently understood. In addition, while VTA-amygdala DA projections
are implicated in the modulation of associative plasticity learning and memory (Robbins
et al., 2008; See et al., 2003), the precise DA receptor-mediated mechanisms (D1 versus
D2 receptor populations) within the BLA that receive opiate-related motivational
information from the VTA are not currently understood.

1.4 Dopamine Transmission and Opiate Reward
DA has been implicated as a critical mediator of central reward transmission.
Indeed, the role of DA as a processor of rewarding sensory stimuli extends to both natural
and/or drug-related stimuli. For example, when highly palatable food or drugs of abuse
are presented, distinct DAergic neuronal populations respond to such stimuli in discrete
patterns of activity (Schultz, 2001). “Rewarding” stimuli, including drugs of abuse,
produce various effects. First, they encourage approach and goal-directed behaviour,
rearranging action priorities. Second, the rewarding effect increases frequency and
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intensity of certain behaviours that elicit the reward, demonstrating a conditioned
learning process. Lastly, rewards produce feelings of pleasure. Studies involving electric
brain stimulating reward have revealed many reward-sensitive sites in the brain, but the
most sensitive site (e.g. the brain system requiring the lowest reward threshold for
eliciting behavioural responding) is the trajectory of the medial forebrain bundle linking
the VTA with the basal forebrain, which includes primarily the mesocorticolimbic
dopamine system (Olds and Milner, 1954). In regard to drug-related rewards, this finding
is further supported by lesion studies of the mesolimbic DA system showing that cocaine
and heroin self-administrations is severely attenuated as a result (Hubner and Koob,
1990).

As previously described, the mesocortiolimbic dopamine system is comprised of
the VTA where the A10 DA neurons reside, sending projections to the NAcc, PFC,
amygdala and many other limbic and cortical regions. Both natural rewards (food and
sexual activity) and drug rewards (opiates) have the ability to increase DA release,
though drug rewards trigger more robust release and do not undergo habituation like
natural stimuli (Di Chiara, 1999; Phillips et al., 1993). This suggests that opiates and
other drugs of abuse can hijack the same reward system implicated in reinforcing effects
of natural stimuli. Moreover, these drugs not only override the reward system, but also
produce persistent effects, not to mention that the associative learning process further
promotes the repeated drug consumption (Berke and Hyman, 2000; Wise, 1996, 1998).
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Besides drug reward, studies have shown that when conditioned stimuli become
valid predictors of reward following a conditioning process, they also acquire the ability
to trigger the firing of dopamine neurons (Schultz, 2001). More recent studies
demonstrate that reward associative learning depends on an error between prediction of
reward and the actual occurrence, and that dopamine neuron activities are intimately
involved in such reward predicting error (Schultz et al., 1993; Schultz, 1997, 2001). It
seems that DA transmission plays multiple roles in reward processing, for example,
acting as salience signal, assigning motivational value to sensory stimuli and signalling
reward predicting error. In addition, other than the positive emotional state, DA signaling
also plays a role in aversive emotional state (fear conditioning) through PFC and BLA
interaction, which further complicates the function of DA transmission in the context of
emotional learning and memory processing (Laviolette et al., 2005; Laviolette and Grace,
2006).

As mentioned previously, most of drugs of abuse including opiates increase DA
concentration

by activating the mesocorticolimbic

DA system.

Studies using

microdialysis procedures are consistent with fMRI data of human opiate addicts, showing
that both opiates and opiate-related cues are able to enhance the activity of this system
(Sell 1997, 1999). The involvement of the DA system in various phases of drug reward
encoding makes it an excellent target for neuroadaptation upon chronic drug exposure
such as functional decrease in neurotransmitter system (Koob and Volkow, 2010). One
prominent hypothesis is that the DA system is comprised during drug addiction and result
in decreased motivation for nondrug stimuli and increased sensitivity for drugs of abuse
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(Melis et al., 2005). Patients who have been chronically exposed to opiates demonstrate
decreased spontaneous firing of DA neurons in the mesocorticolimbic system, indicating
signs of neuroadaptation and opiate’s ability to alter the functionality of DA neurons in
the brain (Volkow et al., 2002). Electrophysiological evidence from chronic morphine
abuser also agrees with the imaging results (Diana et al., 1995). Moreover, another
indicator of neuroadaptation, morphological changes have also been found on DA
neurons within the VTA in chronic morphine withdrawal state (Sklair-Tavron et al. 1996).

Thus, as described above, much evidence indicates that chronic drug exposure and
in particular, chronic opiate exposure, triggers functional and structural alterations at the
DA neuronal level. Does this alteration in DA transmission play a role in the transition
from initial use of opiates to dependent and withdrawal state or are there other
contributing factors? Behavioural studies have shown that microinfusion of DA receptor
antagonist into the VTA is not sufficient to block acquisition of morphine reward;
however it did block morphine reward in morphine-dependent animals, suggesting the
possibility that besides DA transmission, other neurotransmitters or neural pathways
might also be involved in the transition from opiate-naive to opiate-dependent state
(Nader and van der Kooy, 1997). Following up studies done by Laviolette and colleagues
(2004) demonstrate that anatomically distinct neural pathways might be involved in the
opiate reward processing in the opiate-naive versus opiate-dependent and withdrawal
state, and accordingly the brain switches from a DA-independent mechanism to a DAdependent mechanism when opiate dependence is established. Collectively, the evidence
indicates that although opiate class drugs are able to modulate DA transmission
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regardless of exposure state, there is more than one neural system contribute to the
transition to opiate-dependent state. It is likely that DA system might work in conjunction
with other neural substrates to mediate the associative opiate reward learning and
memory.

1.5 Dopamine Receptors and Their Molecular Pathways
Within the CNS, DA receptors are widely expressed and critically involved in
cognition, emotions, and control of locomotion as well as neuroendocrine functions
(Missale et al., 1998). The physiological action of DA is mediated by DA receptors that
are members of the G protein-coupled receptor (GPCR) family with seven
transmembrane domains. There are five types of DA receptors expressed in the CNS,
which fall into two classes with different pharmacological profile. D1 and D5 subtypes
are two D 1-like receptors coupled to G protein Gs subunit, whereas the D2, D3 and D4
subtypes are D2-like receptors that are coupled to G protein Gi subunit (Berke and
Hyman, 2000). Upon DA receptor activation, many signalling pathways are engaged,
among which activation and inhibition of cAMP pathway is best described. Subtypes of
Dl-like receptor are positive regulators of cAMP by activating adenylyl cyclase (AC).
D2-like receptor subtypes are inhibitors of endogenous cAMP by suppressing AC activity
(Vallone et al., 2000). Changes in cAMP level are tightly modulated by DA receptor
activities, and it is not surprising that cAMP plays an important role in the DA receptor
mediated brain functions. Among the five types of DA receptors, the D1 and D2 subtypes
have wider distributions, also more abundant in the CNS, which suggests that a broader
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number of functions are mediated by D1 and D2 subtypes as compared to the other
subtypes (Mansour and Waston, 1995).

Given the role of DA transmission in drug reward, DA receptors are also been
reported to participate in the process. Drug self-administration studies have shown that
both D1 and D2 receptors are involved in the reinforcing properties of drugs of abuse,
and that D1 and D2 receptor agonists themselves have reinforcing properties, capable of
mimicking effect of drugs (Self and Nestler, 1998). Activation of both D1 and D2 type
receptors can have synergic effects on neural activities, gene expression and behaviour,
but some researchers also suggest that D2 receptor activation mediates the stimulating
properties of drug reward, whereas D1 receptor activation plays a permissive role,
meaning that its activation is required for the expressing D2 receptor-mediated behaviour
(Berke and Hyman, 2000; Missale et al., 1998). The exact function of the two classes of
DA receptors is unclear. In terms of opiate reward, it has been reported that DA receptor
agonists attenuates somatic signs of opiate withdrawal, whereas the antagonist induces
signs of withdrawal in morphine-dependent animals and blocks rewarding effect of
morphine, this is especially true for D2 receptors (Harris and Aston-Jones, 1994; Funada
and Shippenberg, 1996; Laviolette et al., 2002). Studies using genetic mouse models also
demonstrate that DA D2 receptor knockout mice showed absence of conditioning to
morphine compare to wild-type littermates, and this effect is specific to morphine since
no difference in behaviour was observed with natural rewards (Maldonado et al., 1997,
Smith et al., 2002).
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Thus, considerable evidence suggests that DA D1 and D2-like receptors play
differential roles in the expression of opiate reward related information and one possible
mechanistic explanation is the involvement of cAMP signalling pathway since activation
of D1 and D2-like receptors differentially regulates the level of cAMP. More importantly,
chronic opiate exposure is known to potently increase regional levels of cAMP in various
neural regions, including the amygdala, VTA and NAcc (Shaw-Luchtman et al., 2002).
Upregulation of secondary messenger cAMP following Dl-like receptor activation can
trigger cAMP-dependent protein kinase (PKA), which then activates transcription factors
and other molecular signalling components that may dysregulate gene expression profiles
required for memory encoding (Self and Nestler, 1998). In addition, D2-like receptor
activation is known to phosphorylate ion channels, such as calcium, sodium, potassium,
and NMDA receptors, therefore interferes with cell firing as well as gene expression
(Berke and Hyman, 2000; Hu and White, 1997). As we know, opiate exposure increases
DA concentration in the mesocorticolimbic system, therefore overstimulate DA receptors,
and prolonged dopamine stimulation causes compensatory cellular adaptations.
Upregulation of cAMP pathway through DA receptors in the NAcc has been identified
after chronic exposure to opiates, and manipulation of this pathway is related to relapse to
drug-seeking behaviour, indicating changes in cAMP signalling pathway as an important
cellular mechanism upon chronic opiate exposure (Self and Nestler, 1995).

1.5.1 Roles for D1 and D2 Receptor Transmission in the BLA
As noted previously, the BLA receives significant DA input from the VTA. While
evidence links this DA projection to the modulation of synaptic plasticity related to
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learning and memory (Bissiere et al., 2002), very little is known regarding the role of DA
receptor transmission within the BLA in the context of associative opiate reward
encoding, nor how ‘opiate exposure state’ may modulate the functional role of this
pathway during opiate-related learning. Within the BLA, both DA D1 and D2 receptors
are expressed and studies have shown that DA levels are increased in the BLA in
response to learning and predictive stimuli (Harmer and Phillips, 1999; Hori et al., 1993).
As discussed previously, the BLA receives projections from PFC and sensory associated
cortical region. During presentation of affective stimuli, DA potentiates the sensory
inputs and attenuates PFC GLUT inputs, which exert inhibitory effect indirectly on the
pyramidal neurons through local GABA intemeurons (Rosenkranz and Grace, 1999).
This observation may lend mechanistic support to the notion that the BLA plays an
important role in associative learning processes linking incoming sensory stimuli with
opiate reward effects. Nevertheless, increasing evidence suggests that DA Dl-like
receptors are located predominantly on post-synaptic locations associated with intrinsic,
GABAergic intemeurons (Missale et al., 1998). In contrast, D2-like receptors have been
reported to be primarily localized to pre-synaptic PFC terminals within the BLA, as
shown in Figure 2 (Pinto and Sesack, 2008). Based on the receptor distribution, DA D1
and D2 receptor activities are able to modulate the input from VTA and PFC during
opiate exposure. Since DA D1 and D2 receptors differentially regulate downstream
intracellular levels of cAMP, we hypothesize that these two subtypes of DA receptor
might exert different effect on the associative opiate reward learning processes by
differentially modulating the encoding of opiate-related associative reward memory as a
function of opiate exposure state.
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Based on the information reviewed above, my thesis project set forth to test the following
specific aims:
1. Determine how differential modulation of DA D1 versus D2 receptor
transmission may modulate the encoding of associative opiate-related reward
information, either via systemic opiate exposure or via intra-VTA opiate
administration.
2. Examine how the state of opiate exposure (drug naive versus dependent and
withdrawn) may modify the functional role of DA D1 versus D2 transmission
within the BLA during the encoding of associative opiate-related reward
information.
3. Characterize the potential role of BLA-NAcc GLUT projections as a functional
pathway mediating intra-BLA D1 versus D2 receptor-mediated modulation of
opiate associative learning.
4. Characterize the downstream molecular events involved in BLA D1 versus D2
receptor-mediated modulation of opiate-related associative reward encoding with
a specific focus on the cAMP signaling pathway.
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Chapter 2 Materials and Methods
This project includes 41 experimental groups ranging from n= 6 to n=9 SpragueDawley rats (Charles River) per group. In the following section, I present all
methodological details pertaining to surgical procedures, drug treatments, and
behavioural paradigms.

2.1 Surgical Procedures
Male Sprague-Dawley rats (Charles River, 350-400g at the start of the
experiments) were anaesthetized with a ketamine (80 mg/ml) xylazine

(6

mg/ml) mixture

and placed into a stereotaxic device. Stainless steel guide cannulae (22 gauge; Plastics
One) were bilaterally implanted into selected brain regions using the following
stereotaxic coordinates (in mm). For the VTA (10° angle): from bregma, AP -5.0, L ±2.3;
from the dural surface, V -8.0. For the BLA: from bregma AP -3.0, L ±5.0; from the
dural surface, V -8.0. For the NAcc shell (12° angle): from bregma, AP ±1.8, L ±2.6;
from the dural surface, V -7.4. At the conclusion of the experiments, animals were deeply
anesthetised and transcardially perfused with isotonic saline followed by

10 %

formalin,

and brains were removed and placed into a formalin-sucrose solution. These brains were
then left in the fridge for a minimum 48 hours prior to slicing using a cryostat machine.
All brain sections were stained with Cresyl violet and the VTA, BLA or NAcc shell
cannulae placements were verified with light microscopy according to the anatomical
boundaries defined by Paxinos and Watson (2005). Animals found to have cannulae
placements outside of the desired brain regions were excluded from analysis.
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2.2 Drug Treatments
Drugs that are used for this project include NMDA receptor antagonist (AP-5,
Sigma), DA D2 receptor antagonist (eticlopride, Sigma), DA D1 receptor antagonist
(SCH 23390, Tocris), heroin (diacetylmorphine, MacFarlane Smith), morphine
(morphine hydrochloride, MacFarlane Smith), DA D2 receptor agonist (quinpirole,
Tocris), DA D1 receptor agonist (SKF 81297, Tocris), rp-cAMP (cAMP inhibitor,
Biomol), and sp-cAMP (cAMP activator, Biomol). All drugs were dissolved in
physiological saline (pH adjusted to 7.4). Bilateral BLA, VTA or NAcc shell
microinjections (0.5gl volume per infusion) were performed over 1 minute via plastic
tubing connected to a 1 pi Hamilton micro-syringe. Injectors were then left in place for an
additional 1 minute to ensure adequate diffusion from the injector tip. For intra-VTA
morphine trials in the antagonist studies, BLA microinfusions of DA D1 or D2 receptor
antagonists were performed immediately prior to VTA microinfusions of morphine. For
intra-NAcc NMDA receptor blockade trials in the agonist studies, NAcc shell
microinfusions of AP-5 were performed immediately prior to BLA microinfusions of
D1/D2 agonist. For the cAMP experiments, intra-BLA administrations of sp-cAMP/rpcAMP were given immediately before intra-BLA DA receptor drugs (agonists or
antagonists). Brain microinfusions were performed immediately prior to systemic
injections of morphine or saline vehicle, and animals were then placed into the assigned
place conditioning environments immediately following systemic injection of morphine
or saline. In the current thesis, we used both ‘sub-reward threshold’ and ‘supra-reward
threshold’ doses of either systemic or intra-VTA morphine. For systemic morphine
administration experiments, a ‘sub-reward threshold’ dose (0.05 mg/kg; i.p.) does not
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normally produce a significant preference for the morphine paired environment, whereas
a ‘supra-threshold’ (0.5-5.0 mg/kg; i.p.) dose produces a significant preference for the
morphine paired environment when tested behaviourally (Bishop et al., 2010). For
experiments using intra-VTA morphine administration, a ‘sub-reward threshold’ dose of
intra-VTA morphine (250 ng/0.5 pi), does not produce a reliable preference for the
morphine-paired environment, whereas a ‘supra-reward threshold’ dose of intra-VTA
morphine (500 ng/0.5 pi) will produce a significant preference for the morphine-paired
environment when tested behaviourally (Laviolette et al., 2004).

2.3 Place Conditioning
All place conditioning procedures used an unbiased, completely counterbalanced
conditioning protocol. Animals were randomly assigned to a treatment group after
recovery from surgery. Animals were conditioned using a fully counterbalanced place
conditioning procedure, as described in following papers: Laviolette and van der Kooy,
2003, Laviolette et al, 2002.

Briefly, the day before the conditioning phase began;

animals underwent a pre-conditioning phase where they were placed in a grey box
(neutral) for 20 minutes. The conditioning process took place in one of the two
environments, which differed in color, texture and smell. The dimensions of the
conditioning boxes were 1 5 X 1 5 inches. One environment was white with a wire mesh
floor that is covered with wood chips that are different from the animal’s home
environment. The other environment was black with a smooth Plexiglass floor that is
wiped down with 2% acetic acid solution before each conditioning session. Thus, the
conditioning environments in our procedure differ in terms of visual, tactile and olfactory
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cues. Environments were balanced based on the treatment received and each environment
was assigned to be either the morphine or saline environment for each animal in a random
manner. As reported previously, animals display no baseline preference for either of these
environments (Laviolette and van der Kooy, 2003). Furthermore, following place
conditioning testing, average times spent in black versus white environments are
compared to ensure that no systemic bias exists for either of the two conditioning
environments.

During conditioning experiments, animals received an equal number of morphineenvironment versus saline- environment pairings. In our

8 -day

conditioning/training

period, they received 4 morphine-environment and 4 saline-environment pairings,
counterbalanced over

8

days (Fig. 4). During testing, animals are placed on a narrow,

separate grey zone that separates the two environments and times spent in each or the two
environments are digitally recorded and scored separately for each animal over a

10 -

minute test session. Animals must have their front two paws and head located in the
environment in order for them to be considered within that environment. Testing is
performed 3-5 days after the last conditioning day for opiate naive animals (Fig. 4A), and
at least 7 days post-conditioning for opiate dependent and withdrawn experimental
groups (Fig. 4B). This waiting period is to assure that animals were being tested in a
drug-free state to rule out any potential motoric influence of remaining drug within their
system during the testing phase.

2.3.1 Induction of Opiate Dependence and Withdrawal
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For studies examining behavioural response in opiate dependent state, animals
were trained in a state of heroin dependency and withdrawal (HDW) as described
previously (Laviolette et al., 2002; 2004). Following pre-conditioning, animals received
daily 0.5 mg/kg subcutaneous injections of heroin commencing 7 days before the start of
conditioning session (Fig. 4B). Animals were then conditioned 21 hours after their last
heroin injection. During conditioning, this dose of heroin was administered as a
maintenance dose 3.25 hours after the termination of each conditioning session. Over the
course of the experiments, animals thus received a total of 15 heroin injections (7 before
conditioning,

8

during conditioning). The aversive effects of withdrawal induced by this

regimen are qualitatively similar to those observed after a 3-week regimen of morphine
administration, which produces aversive motivational effects as well as somatic
withdrawal signs (Laviolette et al., 2004). For experiments examining recovery from
chronic opiate exposure, animals were subjected to a 7-day clearing period (drug free)
after a 7-day heroin treatment as described above (Fig. 4C). The clearing period is again
to assure animals were tested in a drug-free state. Following the clearing period, these
animals then underwent an 8 -day conditioning session without the daily maintenance
dose of heorin. This rapid protocol for the induction of opiate dependence and withdrawal
is advantageous for several reasons. First, as noted above, it produces a state of opiate
dependency and withdrawal that is qualitatively and quantitatively similar to that
observed after a longer, 3-week morphine exposure protocol (Laviolette et al, 2002).
Second, because animals have chronic, indwelling cannulae implantations, a 3-week
opiate exposure protocol would increase the likelihood of developing intra-cranial

F igu re 4

Place conditioning protocol

A. Protocol for opiate naive animals
B. Protocol for opiate dependent and withdrawn animals
C. Protocol for opiate dependent animals after a clearing phase
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infections, a problem which is circumvented by the use of our rapid, 7-day opiate
exposure and withdrawal protocol.

2.4 Data Analysis
All data were analyzed with two-way ANOVA or student’s t-tests where
appropriate. ANOVA was performed for experiments that have multiple groups of
subjects involving one or more independent variables. Post-hoc analyses were then
performed to determine significant group differences within or across levels of analysis.
For post-hoc analysis, Fishers LSD tests were performed when appropriate. For data
presentation, bars on graphs represents group means with error bars representing the
standard error (SEM) of the mean. For results of student’s t-tests and Fishers LSD tests,
one star (*) above a bar graph indicates a level of significance where p < 0.05, and two
stars (**) indicates a level of significance where p < 0.01. Bars below stars that connect
two bar graphs show which two groups are being compared as well as indicating
significant difference, where appropriate.
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Chapter 3 Results
3.1 Effects of Intra-BLA D1 and D2 Receptor Blockade on Opiate
reward encoding

3.1.1 Effect of Intra-BLA DA D1 versus D2 Receptor Blockade on Associative
Opiate Reward Encoding
To compare how blockade of D1 and D2 receptors within the BLA may influence
the encoding of associative reward memory, I first performed intra-BLA bilateral
microinfusions of a DA D1 or D2 receptor antagonist (SCH23390, 0.001-1.0pg/0.5pl; or
Eticlopride, 0.01-1.0pg/0.5pl) in opiate naïve rats, using a supra-reward threshold dose of
systemic morphine (5.0mg/kg; i.p.). I then performed the same intra-BLA D1 or D2
antagonist experiments (SCH23390, 0.1-1.0 pg/0.5pl; Eticlopride, 0.1-1.0pg/0.5pl) to
determine the effects of DA receptor subtype blockade on morphine associative learning
in opiate dependent and withdrawn rats. Histological analysis revealed bilateral cannulae
placements within the BLA as defined by Paxinos and Watson (2005). In Fig. 5A, a
representative microphotograph shows the bilateral injector tip replacements in the BLA.
For clarity, I present an illustrative schematic (Fig. 5B) showing the microinfusion sites
within the BLA from four representative experimental groups.

In previously opiate-naive rats, DA D1 but not D2 receptor blockade within the
BLA disrupts the encoding of associative opiate reward memory
In this experiment, 1 examined the effect of DA D1 versus D2 receptor blockade
within the BLA on the acquisition of CPP for a suprathreshold dose (5mg/kg;
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Figure 5
Histological analysis of intra-BLA cannula placements

A. A microphotograph demonstrating a coronal, Cresyl Violet stained rat brain section of
a representative intra-BLA microinjector tip location.

B. An illustrative schematic of bilateral intra-BLA cannula placements. For clarity, we
show a representative sampling of 4 experimental groups (highest dose in opiate-naive
and opiate-dependent states):
Opiate-naive (Fig. 6)
■ = intra-BLA D1 antagonist (SCH23390, 1.0 pg/0.5 pg) vs. morphine (5mg/kg; i.p.)
□ = intra-BLA D2 antagonist (Eticlopride, 1.0 pg/0.5 pg) vs. morphine (5mg/kg; i.p.)
Opiate-dependent (Fig. 7)
• = intra-BLA D1 antagonist (SCH23390, 1.0 pg/0.5 pg) vs. morphine (5mg/kg; i.p.)
o = intra-BLA D2 antagonist (Eticlopride, 1.0 pg/0.5 pg) vs. morphine (5mg/kg; i.p.)
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intraperitoneal [i.p.]) of morphine in previously opiate naïve rats. In Fig. 6A, results of
CPP testing demonstrate that bilateral intra-BLA microinfusions of the D1 antagonist,
SCH23390, dose-dependently (0.01, 0.1 & 1.0 pg/0.5pl) blocks associative opiate reward
learning in opiate naïve animals as demonstrated by the absence of a CPP response in
these animals. A two-way ANOVA revealed a significant main effect of treatment
(systemic morphine vs. saline) on times spent in saline vs. morphine-paired environments
(F (i, 7i) = 6.72, p< 0.05, Fig. 6A). Post hoc comparisons revealed that saline control
groups receiving intra-BLA saline (n=7, p< 0.01) and the group receiving the lowest dose
(0.001 pg/0.5|il) of intra-BLA SCH23390 (n= 9, p< 0.05) prior to systemic morphine
(5mg/kg), showed a significant place preference for the morphine-paired environment.
The other three doses (0.01, 0.1, 1.0 pg/0.5pl) failed to show a preference for either
saline or morphine-paired environment (p’s >0.05; Fig. 6A). Also, time spent in
morphine-paired environments in animals receiving the highest dose of intra-BLA
SCH23390 (1.0 pg/0.5pl) were significantly decreased relative to times spent in
morphine

environments

in

saline

control

animals

(n=7,

p<0.05).

Moreover,

administration of the highest dose (1.0 pg/0.5|j.l) resulted in a slight trend towards
aversion to morphine-paired environment, but this effect is not statistically significant.
These experiments demonstrate that the pharmacological blockade of DA D1 receptors
transmission within the BLA dose-dependently blocks associative opiate reward learning
specifically in opiate-naive rats.

We next performed intra-BLA bilateral microinfusions of the DA D2 receptor
antagonist (Eticlopride; 0.01-1.0 pg/0.5pl) in previously opiate naive animals, again
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Figure 6
Effects of intra-BLA DA D1 vs. D2 receptor blockade on opiate reward memory
encoding in the opiate-na'ive state

A. The saline control and a treatment group receiving the lowest dose of intra-BLA D1
antagonist, SCH23390 (0.001 pg/0.5 pi) versus a supra-threshold dose (5mg/kg; i.p.) of
morphine show a preference for the morphine paired environment. An order of magnitude
higher dose of intra-BLA SCH23390 (0.01 pg, 0.1 pg, and 1.0pg/0.5 pi) versus the same
dose of morphine (5mg/kg; i.p.), fails to produce a preference for either conditioning
environment.

B. The saline control (taken from D1 antagonist experiment) and all three treatment
groups of the intra-BLA D2 antagonist, Eticlopride (0.01 pg, 0.1 pg, and 1.0pg/0.5 pi)
versus a supra-threshold dose of morphine (5mg/kg; i.p.), demonstrate a place preference
for the morphine-paired environment.
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using a supra-threshold dose (5.0mg/kg; i.p.) of morphine as the conditioning dose. As
shown in Figure 6B, CPP test results reveal that intra-BLA D2 antagonist (Eticlopride)
administration prior to systemic morphine (5.0 mg/kg; i.p.) does not disrupt associative
reward learning in the opiate naïve state, as demonstrated by a strong preference for the
morphine-paired environment. A two-way ANOVA showed a significant main effect of
treatment (systemic morphine vs. saline) on the time spent in saline vs. morphine-paired
environment (F (i; 55) = 58.42, p< 0.001). Post hoc comparisons show that none of the
three doses of intra-BLA Eticlopride (0.01, 0.1 & 1.0 pg/0.5pl; Fig. 6B) influenced the
rewarding effects of morphine as all groups demonstrated a strong CPP for the morphine
paired environments (n = 7, p < 0.01; n = 6 , p < 0.05; n = 7, p < 0.01). These results
demonstrate that D2 receptor blockade in the BLA is not effective in blocking morphine
reward learning in the opiate naive state. Therefore, in previously opiate naïve rats, DA
D1 but not D2 receptor transmission is required for the encoding of associative opiate
reward learning.

In opiate-dependent rats, DA D2 but not D1 receptor blockade within the BLA
disrupts the encoding of associative opiate reward memory
In our next series of experiments, I examined the effects of intra-BLA D1 or D2
receptor blockade in rats trained in a state of opiate dependence and withdrawal (see
methods). In our first experiment, these rats received bilateral intra-BLA microinfusion
of the D1 antagonist (SCH23390) using the previously established effective doses (the 2
higher doses in naïve animals, 0.1 & 1.0 pg/0.5pl) prior to receiving systemic morphine
(5mg/kg, i.p.) injection. ANOVA revealed a significant main effect of treatment

49

(systemic saline vs. morphine) on times spent in saline vs. morphine-paired environments
(F (1, 43) = 182.19, p < 0.001, Fig. 7A). Post hoc comparisons showed that, similar to
saline control rats, (n = 7, P < 0.01), rats receiving the two effective doses (0.1,
1.0pg/0.5pl) of intra-BLA SCH23390 followed by systemic morphine (5mg/kg, i.p.)
displayed strong CPP for the morphine-paired environment (0.1 pg/0.5pl, n =

8;

l.Opg/O.Spl, n = 7, p’s < 0.01). In contrast to what we observed in opiate-naive rats, these
two doses of the intra-BLA D1 antagonist (SCH23390) were unable to block the
associative rewarding effects of morphine in rats chronically treated with opiates and in
withdrawal (Fig. 7A).

In our next experiment, opiate-dependent rats received bilateral intra-BLA
microinfusion of the DA D2 receptor antagonist (Eticlopride), also using the two
effective doses (0.1 & 1.0 pg/0.5pl) established in our first set of experiments performed
in opiate naive rats, prior to receiving systemic morphine (5mg/kg, i.p. Fig. 7B). A twoway ANOVA revealed a significant group (intra-BLA saline vs. Eticlopride) X treatment
(systemic saline vs. morphine) interaction on times spent in saline vs. morphine-paired
environments (F (2, 41) = 6.14, p < 0.01). Post hoc tests revealed that animals receiving the
lower dose (0.1pg/0.5pl; n = 7, p < 0.01) of intra-BLA Eticlopride or saline control rats
(n = 7, p < 0.05), showed strong CPP for morphine-paired environments. However, rats
receiving the higher dose of intra-BLA eticlopride (1.0 pg/0.5 pi) showed no CPP for the
morphine paired environment (n = 7, p > 0.05). In addition, time spent in morphinepaired environments in animals receiving the highest dose of intra-BLA Eticlopride
(1.0pg/0.5pl) were significantly decreased relative to times spent in morphine
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Figure 7
Effect of intra-BLA DA D1 vs. D2 receptor blockade on opiate reward memory
encoding in opiate-dependent state

A. Three groups of opiate-dependent animals received intra-BLA saline, the D1
antagonist (SCH23390) at 0.1 pg/0.5pl and SCH23390 at 1.0 |ig/0.5pl accordingly, prior
to receiving systemic morphine (5mg/kg, i.p.). Both control and treatment groups display
a strong preference for morphine-paired environments, demonstrating that two effective
doses of intra-BLA SCH23390 (0.1 & 1.0 pg/0.5pl) established from previous naive
animal experiments did not interfere with the ability of morphine reward learning in
opiate-dependent animals.

B. Control group data is taken from the above experiment for ease of comparison, intraBLA microinfiision of low dose (0.1pg/0.5pl) D2 antagonist (Eticlopride) did not prevent
supra-threshold morphine (5mg/kg, i.p.) to result in a positive CPP; whereas intra-BLA
Eticlopride at a high dose (1.0 pg/0.5pl) abolishes the CPP response, meaning that
microinfusion of Eticlopride at a high dose (1.0 pg/0.5pl) within the BLA blocks
associative reward memory encoding in the opiate-dependent state.
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environments in saline control animals (n=7, p <0.05, Fig. 7B). Therefore, during the
opiate dependent and withdrawn state, the encoding of associative opiate reward requires
DA D2 receptor transmission within the BLA, but not DA D1 receptor transmission, a
functional reversal from what we observed in the opiate-naive state.

I have thus far observed a double dissociation phenomenon for DA D1 vs. D2
receptor transmission within the BLA in a function of opiate exposure state (naive vs.
dependent/withdrawn opiate exposure states), that is BLA DA D1 receptor transmission
is essential for associative opiate reward learning in the opiate-naive state, whereas BLA
DA D2 receptor transmission is only required during the opiate-dependent and withdrawn
state.

3.1.2 VTA-BLA Interaction
It has become well established that opiates bind to p-opioid receptors located on
GABAergic intemeurons in the VTA (Fig. 2), resulting in a disinhibition of the DAergic
projection neurons that leads to amplified DA output to various brain regions (Svingos et
al., 2001). As demonstrated in our model (Fig. 1), I propose that the primary opiate
reward information coming from the VTA is sent to the BLA via DA transmission. In my
next series of experiments, I examined how manipulation of DA D1 and D2 receptors
within the BLA may modulate opiate reward information from the VTA, using D1
receptor antagonist (SCH23390) and D2 receptor antagonist (Eticlopride) at our
previously established effective dose range (1.0 pg/0.5pl). All rats for these experiments
underwent quadruple cannulation surgeries and had two cannulae in the BLA and two in
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Figure 8
Histological analysis of intra-VTA cannula placements

A. A microphotograph demonstrating Cresyl Violet stained coronal rat brain section of
representative intra-VTA microinjector tip location.

B. An illustrative schematic of bilateral intra-VTA cannula placements. For clarity, we
show a representative sampling of 2 effective groups:
■ = intra-VTA morphine (0.5 pg/0.5 pi) and intra-BLA D1 antagonist (SCH23390, 1.0
pg/0.5 pi) in opiate-naive rats
□ = intra-VTA morphine (0.5 pg/0.5 pi) and intra-BLA D2 antagonist (Eticlopride, 1.0
pg/0.5 pg) in opiate-dependent rats

54

-5.28

55

Figure 9
Effect of intra-BLA DA D1 vs. D2 receptor blockade on intra-VTA opiate reward
memory encoding in the opiate-naive versus opiate-dependent state

A. Opiate-naive animals that received microinfusions of the intra-BLA D1 antagonist
(SCH23390, 1.0 fj.g/0.5 pi) or saline vehicle prior to intra-VTA morphine (0.5pg/0.5 pi)
fail to produce a positive CPP for morphine environment, whereas opiate-dependent
animals that received that same treatment showed a significant positive CPP.

B. Opiate-dependent animals that received microinfusions of the intra-BLA D2
antagonist (Eticlopride, 1.0 pg/0.5 pi) or saline control prior to intra-VTA morphine
(0.5pg/0.5 pi) did not produce a positive CPP, however, opiate-naive animals receiving
that same treatment display a positive CPP for the morphine environment.
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the VTA. Figure 8A shows a microphotograph demonstrating a representative intra-VTA
microinfusion site, and an illustrative schematic in Fig. 8B shows intra-VTA
microinjector tip locations from two representative experimental groups. In each of the
experiments, the effective dose (1.0 pg/0.5pl) of D1 or D2 receptor antagonists was
microinfiised into the BLA immediately before 0.5pg/0.5pl morphine was microinfused
into the VTA (see methods).

Effects of intra-BLA D1 receptor blockade on the processing of intra-VTA opiate
reward
Blockade of intra-BLA D1 receptor transmission produced the same double
dissociation for the encoding of intra-VTA morphine reward signalling as that observed
in our systemic morphine experiments.

A two-way ANOVA revealed an interaction

between group (saline control vs. drug treatment groups) and treatment (systemic saline
vs. morphine) on times spent in saline versus morphine-paired environments (F (i, 40) =
9.32, p < 0.01, Fig. 9A). Post hoc tests revealed that opiate naïve animals receiving intraBLA saline control (n=8 , p<0.05) and opiate dependent animals receiving intra-BLA D1
antagonist (SCH23390, 1.0 |ig/0.5pl) prior to intra-VTA morphine (0.5pg/0.5pl)
demonstrated a significant CPP for the intra-VTA morphine-paired environment (n= 7,
p ’s < 0.01), whereas opiate naïve rats that received intra-BLA SCH23390 at the same
dose, demonstrated no preference for either morphine or saline-paired environment (n = 8 ,
p > 0.05). Also, times spent in morphine-paired environments in opiate dependent rats
treated with SCH23390 was significantly increased compare to times spent in morphine
environment in naïve rats treat with SCH23390 (n=7 , p < 0.01). These results
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demonstrate that DA D1 receptor blockade in the BLA disrupts the encoding of morphine
reward signalling directly from the VTA in previously opiate naïve rats, but not in opiate
dependent rats.

Effects of intra-BLA D2 receptor blockade on the processing of intra-VTA opiate
reward
Blockade of intra-BLA D2 receptor transmission produced the same double
dissociation for the encoding of intra-VTA morphine reward signalling as that observed
in our systemic morphine experiments. A two-way ANOVA revealed a significant
interaction between group (saline control vs. drug treatment groups) and treatment
(systemic saline vs. morphine) on times spent in saline versus morphine-paired
environments (F (2, 45) = 4.24, p <0.05). Post hoc analyses revealed that opiate dependent
rats receiving microinfusions of the intra-BLA D2 antagonist (Eticlopride, 1.0 pg/0.5pl)
prior to morphine (0.5pg/0.5pl) in the VTA, failed to show preference for either
morphine or saline-paired environments (n =

8,

p > 0.05, Figure 9B). However, in

opiate-naive rats, intra-BLA D2 receptor blockade or as saline failed to prevent the
encoding of intra-VTA morphine reward, as both groups demonstrated a robust CPP for
the intra-VTA morphine paired environments (p’s < 0.05). Thus, similar to our
previously observed effects with systemic morphine administration, DA D2 receptor
blockade in the BLA blocked the encoding of associative opiate reward learning only in
the opiate-dependent and withdrawn state, but not in the drug naïve condition further
confirming a functional switch from a D1-receptor mediated to a D2 receptor-mediated
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intra-BLA opiate reward encoding substrate, as a function of opiate exposure state, as
previously observed with systemic morphine administration (Fig. 6 and Fig. 7).

3.1.3 Functional Plasticity of the Intra-BLA DA D1/D2 Switch after Recovery from
Opiate Exposure
So far, I have observed that opiate-naive and opiate-dependent animals react
differently to DA D1 and D2 receptor blockade in the BLA in terms of opiate reward
encoding, demonstrating a functional switch between BLA DA D1 and D2 receptor
transmission according to opiate exposure state. However, a critical question is whether
or not this switch from a D1 receptor-dependent to a D2 receptor-dependent mechanism
for opiate reward encoding is permanent after opiate exposure, or is only functionally
operational during the actual state of opiate dependence and withdrawal? Thus, in my
next study, I pre-exposed experimental groups to our previously described chronic opiate
exposure protocol (see methods) and after allowing a period of recovery from opiate
exposure, re-tested whether intra-BLA D1 or D2 receptor blockade would produce
similarly dissociable effects on opiate reward processing (see methods for further details).

Effects of intra-BLA D1 receptor blockade after chronic opiate recovery
In rats chronically exposed to opiates but then allowed to recover, intra-BLA D1
receptor blockade produced the same effects as those observed in the opiate-naive state.
A two-way ANOVA revealed a significant effect of an interaction between group (3
states of exposure) and treatment (systemic saline vs. morphine) on the time spent on
saline versus morphine environment (F (2, 41) = 7.24, p < 0.01, Fig. 10A). For ease of
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Figure 10
Effect of intra-BLA D1 or D2 receptor blockade on opiate reward memory encoding
after recovery from chronic opiate exposure

A. For comparison purposes, data for the last two bar graphs (controls) were taken from
previous experiments examining the effect of the intra-BLA D1 antagonist (SCH23390,
1.0(ig/0.5pl) with systemic supra-threshold morphine (5.0mg/kg). Opiate-dependent
(HDW) rats display a place preference for morphine paired environment, whereas opiate
naive rats and HDW failed to do so following recovery (clearing period) from opiate
exposure.

B. For comparison purposes, data for the last two bar graphs (controls) were taken from
previous experiments examining the effect of the intra-BLA D2 antagonist (Eticlopride,
1.0pg/0.5 pi) with systemic supra-threshold morphine (5.0mg/kg). Opiate naive rats and
HDW rats after a clearing period displayed a CPP for morphine paired environment,
whereas HDW rats failed to do so.
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comparison, I have taken data from previous experiments (opiate-naive and opiate
dependent state) to serve as controls. Post hoc analyses show that opiate-dependent
animals receiving intra-BLA microinfusion of SCH23390 (1.0pg/0.5 pi, previously
established dose) showed a place preference for morphine-paired environment (n = 7, p <
0.01). However, with the same drug treatment (SCH23390, 1.0pg/0.5 pi), opiate-naive
rats and opiate-dependent rats after clearing did not display a preference for morphinepaired environment (both n=7, p’s > 0.05). Also, opiate dependent rats spent significant
more time in morphine-paired environment relative to opiate naive rats (n=7, p <0.05).
The results indicate that opiate-dependent animals after a clearing period produce the
same behavioural response to intra-BLA D1 blockade as opiate naive animals, but not
normal opiate dependent animals (Fig. 10A).

Effects of intra-BLA D2 receptor blockade after chronic opiate recovery
In rats chronically exposed to opiates but then allowed to recover, intra-BLA D2
receptor blockade produced the same effects as those observed in the opiate-naive state
(Fig. 10B). ANOVA showed a significant interaction between groups (3 states of
exposure) and treatment (systemic saline vs. morphine) on time spent in saline vs.
morphine-paired environment (F (2, 41) = 6.51, p < 0.01). Again, I have taken data from
previous experiments (opiate-naive and opiate-dependent state) as our controls for
comparison purposes. Post hoc comparisons show that when microinfusions of the intraBLA D2 antagonist (Eticlopride, 1.0pg/0.5pl) prior to systemic morphine (5mg/kg, i.p.)
are performed across groups (Fig. 10B), opiate dependent rats failed to show a place
preference for morphine-paired environment (n = 7, p > 0.05), whereas opiate-naive rats
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and opiate-dependent rats recovered from opiate exposure displayed a positive CPP for
morphine-paired environment (n =7, p < 0.01; n = 7, p < 0.05). In addition, opiate naive
rats spent significantly more time in the morphine-paired environment compared to opiate
dependent rats receiving the same drug treatment (n=7, p<0.05). These results
demonstrate that once recovery from chronic opiate exposure has taken place, the effects
of D2 receptor transmission within the BLA revert to the opiate naive state.

From sections 3.1.1 to 3.1.2, I have determined that there is a functional switch
between DA D1 and D2 receptor within the BLA according to opiate exposure state, and
that BLA D1 receptor transmission is essential for associative reward learning in the
opiate-naive state, whereas DA D2 receptor transmission is required only in the opiatedependent and withdrawn state. Finally, I have shown that the effects of chronic opiate
exposure upon the functional properties of intra-BLA D1 or D2 receptor signalling are
not permanently altered by opiate exposure, but rather, functionally revert back to the non
opiate dependent state once recovery from opiate exposure has occurred.

3.2 Effects of intra-BLA D1 versus D2 Receptor Activation on Opiate
Reward Encoding
Given my previous findings demonstrating opposing functional effects of intraBLA D1 or D2 receptor transmission during opiate reward encoding, I hypothesized that
pharmacologically activating intra-BLA D1 versus D2 receptor within the BLA may
produce the behaviourally opposite effect to that observed with D1 and D2 receptor
blockade. That is, will intra-BLA D1 versus D2 receptor activation ‘potentiate’ the
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rewarding effects of opiates? If so, will this opiate reward potentiation follow the same
functional boundary between the opiate naive versus dependent/withdrawn exposure
states? Finally, which output from the BLA may mediate this effect? I hypothesized that
GLUT outputs from the BLA to the NAcc shell may be responsible for the ability of
intra-BLA D1/D2 transmission to modulate opiate reward magnitude (for further details
see methods and discussion) In Fig. 11 A, a representative microphotograph shows a
representative bilateral injector tip placements in the NAcc shell region. For clarity, I
present an illustrative schematic (Fig. 11B) showing the microinfusion sites within the
BLA from 2 representative experimental groups.

3.2.1 Activation of Intra-BLA DA D1 Receptors Potentiates subthreshold morphine
Reward Encoding in Opiate Naïve Rats
I performed intra-BLA microinfusions of DA D1 agonist (SKF81297) in both
opiate-naive (0.1 &1.0pg/0.5pl) and opiate-dependent rats (1.0pg/0.5 pi) followed by
systemic administration of a sub-reward threshold dose of morphine (0.05mg/kg; see
methods). A two-way ANOVA revealed a significant effect of interaction between
groups (intra-BLA saline vs. 3 drug treatment groups) and treatment (saline vs. morphine)
on time spent in saline versus morphine-paired environment (F (3, 59) = 3.37, p < 0.05, Fig.
12A). Post hoc analyses revealed that control animals that received intra-BLA saline prior
to the sub-threshold dose of morphine (0.05mg/kg, i.p.) did not develop a preference for
the morphine-paired environment (n = 7, p > 0.05), demonstrating that this 0.05mg/kg
dose of systemic morphine is not sufficient to induce a CPP response. I observed the
same response with opiate naïve animas receiving a low dose the intra-BLA D1 agonist
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Figure 11
Histological analysis of intra-NAcc shell cannula placements

A. A microphotograph demonstrating Cresyl Violet stained coronal rat brain section of a
representative intra-NAcc shell microinjector tip location.

B. An illustrative schematic of bilateral intra-NAcc cannula placements. For clarity, we
show a representative sampling of 2 experimental groups:
■ = intra-NAcc AP-5 (1.0pg/0.5 pi) and intra-BLA D1 agonist (SKF81297, 1.0 pg/0.5 pi)
in opiate-naive rats
□ = intra-NAcc AP-5 (1.0pg/0.5 pi) and intra-BLA D2 agonist (Quinpirole, 1.0 pg/0.5 pi)
in opiate-dependent rats
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Figure 12
Potentiation of a conditioned place preference (CPP) by DA receptor activation
within the BLA in opiate-na'ive and opiate-dependent states

A. In the opiate naive state, animals receiving intra-BLA saline (control) and low dose
D1 agonist (SKF81297, 0.1pg/0.5pl) prior to a subthreshold dose of morphine
(0.05mg/kg, i.p.) did not show a preference for either saline or morphine-paired
environments. At a higher dose of the intra-BLA D1 agonist (SKF81297, 1.0pg/0.5pl),
animals showed a positive CPP response, but opiate dependent animals receiving intraBLA D1 agonist SKF81297 at the same dose failed to do so. The bar graph on the left
panel shows that opiate naive animals receiving intra-NAcc shell NMDA antagonist AP-5
(1.0pg/0.5pl) failed to produce a positive CPP for morphine paired environment.
B. In the opiate-dependent state, a subthreshold dose of morphine (0.05mg/kg, i.p.) failed
to produce a significant CPP in animals receiving intra-BLA saline and a lower dose of
the D2 agonist (Quinpirole, 0.1pg/0.5|il), whereas animals receiving the intra-BLA D2
agonist at a higher dose (1.0pg/0.5pl) demonstrated a significant CPP. Opiate-naive rats
receiving the same high dose of the D2 agonist in the BLA did not show a place
preference. The bar graph on the left panel shows that opiate dependent animals receiving
pretreatment with the intra-NAcc shell NMDA antagonist AP-5 (1.0pg/0.5pl) failed to
produce a positive CPP for morphine paired environment.
C. In the opiate naive state, both saline control and animals receiving intra-NAcc shell
AP-5 (1.0pg/0.5pl) demonstrate a positive CPP for a just supra-threshold dose of
systemic morphine (0.5mg/kg, i.p.)
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F81297, 0.1 fxg/0.5(j.l) and in opiate dependent rats receiving the high dose SKF 81297
(1,0|ig/0.5pl) prior to subthreshold dose (0.05mg/kg, i.p.) of morphine (n = 8 , n = 7; both
p > 0.05). However, when I administered a higher dose of D1 agonist (SKF81297,
1.0|ig/0.5(il) into the BLA before systemic 0.05mg/kg morphine, previously opiate naive
rats demonstrated a strong place preference for the morphine-paired environment (n = 8 ,
p < 0.01. Fig 12A), demonstrating that intra-BLA D1 receptor activation can dosedependently potentiate normally sub-reward threshold doses of morphine, only in the
opiate naïve state. As described in the methods section, I tested whether GLUT
projections from the BLA to the NAcc shell region may be involved in the observed
effects of intra-BLA D1 receptor activation on morphine reward potentiation. As
presented in the left panel of Figure 12A, blockade of GLUT transmission within the
NAcc shell via pre-administration of the competitive NMDA receptor antagonist, AP-5,
(1.0 pg/0.5pl) prior to intra-BLA D1 agonist (SKF81297, 1.0pg/0.5pl) completely
blocked the ability of intra-BLA D1 receptor activation to potentiate a normally sub
reward threshold dose of morphine as these rates did not show place preference for either
saline or morphine paired environment (n= 8 , t (7) = 0.63, p >0.05). These results indicate
that DA D1 receptor activation potentiates a CPP for subthreshold morphine reward in
opiate-naive rats but not opiate-dependent rats. Furthermore, GLUT transmission via
NMDA receptors within the NAcc shell, possibly via GLUTergic projections from the
BLA to NAcc, may play an important role in this D1 mediated reward potentiating effect
via the BLA.
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3.2.2 DA D2 Agonist Potentiates Subthreshold Morphine Reward in Opiate
Dependent Rats
Next step, I performed the same procedures with DA D2 receptor agonist
(Quinpirole). In Figure 12B, Opiate-dependent animals receiving saline in the BLA
followed by subthreshold dose (0.05mg/kg, i.p.) of morphine failed to show a preference
for either saline or morphine-paired environment (n =

8,

t (7) = - 0.38, p > 0.05),

indicating 0.05mg/kg systemic morphine is not sufficient to produce a positive CPP
response. I then administered a lower dose of D2 agonist (Quinpirole, 0.1pg/0.5pl) in the
BLA prior to subthreshold dose of morphine (0.05mg/kg, i.p.) and I did not observe a
place preference for either one (n = 8 , t (7) = 1.03, p > 0.05), indicating that low dose of
intra-BLA D2 agonist was not able to potentiate a positive CPP response in opiatedependent rats. However, when I used a higher dose (intra-BLA Quinpirole, 1.0gg/0.5pl),
opiate-dependent animals displayed a strong place preference for morphine-paired
environment (n = 7, t (6) = - 4.73, p < 0.01, Fig. 12B), which suggests that intra-BLA D2
agonist Quinpirole at a high dose (1.0pg/0.5|il) is able to potentiate a positive CPP
response in opiate-dependent rats. When I repeat the experiment (Quinpirole, 1.0pg/0.5pl)
using opiate-naive rats with systemic subthreshold morphine (0.05mg/kg), I did not see a
place preference for either environment (n = 7, t (6) = 0.18, p > 0.05), suggesting that
intra-BLA D2 agonist Quinpirole at a high dose (1.0pg/0.5pl) is unable to potentiate a
positive CPP response in opiate-naive rats. Similar to my experimental rationale
described above, I tested whether GLUT projections from the BLA to the NAcc shell
region may be involved in the observed effects of intra-BLA D2 receptor activation on
morphine reward potentiation. As presented in the left panel of Fig. 12B, blockade of
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GLUT transmission within the NAcc shell via pre-administration of the competitive
NMDA receptor antagonist, AP-5, (1.0 p.g/0.5(_il) prior to intra-BLA D2 agonist
(Quinpirole, 1.0pg/0.5pl) completely blocked the ability of intra-BLA D2 receptor
activation to potentiate a normally sub-reward threshold dose of morphine as these rates
did not show place preference for either saline or morphine paired environment (n= 8 , t (7)
= 1.14, p >0.05). These results indicate that DA D2 receptor activation potentiates a CPP
for subthreshold morphine reward in opiate-dependent/withdrawn rats but not opiatenaive rats. Furthermore, GLUT transmission via NMDA receptors within the NAcc shell,
possibly via GLUTergic projections from the BLA to NAcc, may play an important role
in this D1 mediated reward potentiating effect via the BLA.

I found that intra-NAcc shell infusions of AP-5 were able to block the
potentiation of sub-reward threshold doses of morphine (far left panels, Fig. 12A, B).
However, an alternative explanation is that blockade of intra-NAcc shell NMDA receptor
transmission may simply produce a non-specific learning deficit, wherein rats are unable
to form any associative memory. Thus, to rule out the possibility that AP-5 in the NAcc
shell disrupts the ability of rats to acquire any opiate-related associative learning, I
performed an additional control study wherein rats received bilateral microinfusions of
intra-NAcc shell AP-5 (1.0pg/0.5pl) followed by a just supra-reward threshold dose of
morphine (0.5 mg/kg, i.p., Fig. 12C). A two-way ANOVA analyses reveal a significant
interaction between (saline control and AP-5 treated group) and treatment (systemic
morphine vs. saline) on time spent in either morphine or saline paired environment (F q,
23)

= 4.91, p <0.05). Post hoc comparison shows that both control and drug treatment
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groups showed a positive CPP towards the morphine paired environment (both p <0.05),
indicating that AP-5 alone in the NAcc shell does not produce any non-specific learning
or memory deficits.

Comparing the effect of both drugs, we see that DA D1 and D2 receptor
activation in the BLA potentiate the rewarding properties of subthreshold morphine and
that such reward potentiation similarly follows the functional ‘switching’ dissociation
between the opiate-naive and opiate-dependent/withdrawn states, as we have observed
with the intra-BLA D1/D2 antagonist studies.

3.3 Effects of cAMP Modulation on D1 and D2 Receptor-mediated
Modulation of Opiate Reward Encoding
Although the pharmacological studies enable us to understand the behavioural
function of D1 and D2 receptors in the BLA in the context of opiate reward encoding, it
is unclear what underlies the double dissociation of the two types of receptors. As
described in the introduction, DA receptors belong to G-protein coupled receptors (GPCR)
family, which are linked to the downstream secondary messenger cAMP cascade.
Activation of D1 family receptors increases the concentration of cAMP, whereas
activation of D2 family receptors deceases the concentration of cAMP (Dailey and
Everitt, 2009). This bidirectional control of cAMP levels via D1/D2 receptor transmission
suggests an interesting molecular target for us in the context of our studies. The goal of
this group of experiments is to determine whether the change in cAMP concentrations
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following the actions of DA D1 and D2 receptor agonists and antagonists in the BLA
may underlie our observed effects on opiate reward encoding.

3.3.1 Effects of Intra-BLA cAMP Inhibition or Activation on Opiate Reward
Encoding
In my first study, I used the cAMP inhibitor (Rp-cAMP) and cAMP activator (SpcAMP) to manipulate cAMP concentration in the BLA. If cAMP concentration is the
underlying factor of the double dissociation phenomenon, I predicted that cAMP
inhibition or activation would mimic the effect of D1 and D2 receptor drugs and also
interfere with the ability to encode opiate reward memory in a manner analogous to that
observed following intra-BLA D1 or D2 receptor blockade (Sections 3.1/3.2).

Effects of intra-BLA cAMP inhibition on morphine reward encoding
Given that D1 receptor activation normally would be expected to increase cAMP
levels, I hypothesized that D1 antagonism in the BLA may block opiate reward encoding
(in the opiate naïve state) by decreasing endogenous levels of cAMP. Therefore, in my
next study, I performed the same experimental procedure described above, but using a
cAMP inhibitor (Rp-cAMP, 0.5pg/0.5pl) to determine if cAMP inhibition may mimic the
behavioural effects of intra-BLA D1 antagonism. To determine the effects of cAMP
inhibition on the encoding of morphine reward, I administered a cAMP inhibitor (RpcAMP, 0.5pg/0.5|il) into the BLA followed by administration of a suprathreshold dose of
morphine (5mg/kg; i.p., Fig. 13A) in opiate naïve rats, comparing this to rats receiving
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Figure 13
Effect of cAMP level manipulation within the BLA on opiate-related learning in
opiate-naive and opiate-dependent rats

A. For comparison purposes, the first two bar graphs are taken from previous experiments
investigating effect of intra-BLA saline and D1 antagonist SCH23390 (1.0pg/0.5pl)
accordingly and the third bar graph showing effect of cAMP inhibitor, Rp-cAMP
(0.5|ig/0.5pl). Control naive rats treated with intra-BLA saline showed a positive CPP for
systemic supra-threshold dose of morphine. Whereas, naive rats treated with intra-BLA
SCH23390 and Rp-cAMP did not show a CPP for morphine paired environment.

B. For comparison purposes, the first two bar graphs are taken from previous experiments
investigating effect of intra-BLA saline and D2 antagonist Eticlopride (1.0pg/0.5pl) and
the third bar graph showing effect of cAMP activator, Sp-cAMP (0.5pg/0.5pl). Control
HDW rats treated with intra-BLA saline showed a positive CPP for systemic
suprathreshold dose of morphine. Whereas, HDW rats treated with intra-BLA Eticlopride
and Sp-cAMP failed show a place preference.
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BLA saline. A two-way ANOVA revealed a significant group (saline control vs. drug
treatment groups) and treatment (systemic saline vs. morphine) interaction on time spent
in saline vs. morphine-paired environment (F (2, 43) = 8.77, p < 0.01). Post hoc analyses
show that the saline control group demonstrated a significant CPP for a supra-reward
threshold (5mg/kg, i.p) morphine reward (n = 7, p < 0.01), whereas opiate naive rats
treated with the intra-BLA D1 antagonist (SCH23390, 1.0pg/0.5pl) or cAMP inhibitor
(Rp-cAMP, 0.5pg/0.5(il) failed to show a place preference for either saline or morphinepaired environment (both n=8 , p’s > 0.05, Fig. 13A), indicating that pharmacologically
decreasing cAMP concentration in the BLA interferes with associative opiate reward
learning. In addition, times spent in morphine-paired environments in animals receiving
intra BLA SCH23390 or Rp-cAMP were significantly decreased relative to times spent in
morphine environments in saline control animals (n=7, p<0.01; n= 8 , p<0.05). These
experiments demonstrate that cAMP inhibition (Rp-cAMP) produces a functionally
similar effect to that of intra-BLA D1 antagonists, as both are able to block the formation
of morphine CPP in opiate naive rats.

Effects of cAMP activation on morphine reward encoding
Given that D2 receptor activation normally would be expected to decrease cAMP
levels, I hypothesized that D2 receptor antagonism in the BLA (during the opiatedependent and withdrawn state) may block opiate reward encoding by increasing
endogenous levels of cAMP. Therefore, in my next study, I performed the same
experimental procedure described above, but using a cAMP activator (Sp-cAMP,
0.5|ig/0.5|il) to determine if cAMP activation may mimic the behavioural effects of intra-
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BLA D2 antagonism. A two-way ANOVA showed a significant group (saline control vs.
drug treatment groups) and treatment (systemic saline vs. morphine) interaction on time
spent in saline vs. morphine-paired environment (F (2, 43) = 7.31, p <0.01, Fig. 13B). Post
hoc tests revealed that saline control animals displayed a positive CPP for suprathreshold
morphine reward (5 mg/kg; i.p.; n = 7, p < 0.01). However, opiate dependent rats
receiving intra-BLA microinfusions of D2 antagonist (Eticlopride, 1.0pg/0.5pl) and
cAMP activator (Sp-cAMP, 0.5pg/0.5pl) following suprathreshold dose of morphine
(5mg/kg, i.p.) failed to show a place preference for either saline or morphine-paired
environment (n = 8 , n = 7, both p > 0.05). Thus, similar to the effects of intra-BLA D2
receptor blockade, cAMP activation (Sp-cAMP) can blocks opiate-related learning when
administered into the BLA in the opiate-dependent rats, demonstrating an analogous
functional pathway shared between the D2 receptor and associated cAMP signalling
cascades.

3.3.2 Effects of cAMP Modulation in the BLA on D1 and D2 Mediated Modulation
of Opiate Reward Encoding
Given the fact that BLA DA receptors are GPCRs, activation and inactivation of
these receptors are linked to the rise and fall of downstream cAMP levels. Accordingly, I
hypothesized that co-administration of pharmacological modulators of cAMP with
previously established effective doses of intra-BLA D1/D2 receptor agonists and
antagonists, may be able to reverse the functional effects of intra-BLA DA D1 or D2
receptor manipulations during opiate reward encoding.
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Pharmacological modulation of intra-BLA cAMP levels reverses the behavioural
effects of D1 or D2 receptor blockade on opiate reward encoding
Our antagonist studies in section 3.1 showed that DA D1 and D2 receptor
blockade within the BLA blocked opiate-related learning as a direct function of opiate
exposure state (Fig. 6 & Fig. 7). The goal of following experiments was to determine
whether cAMP level manipulation in the BLA can prevent the blocking action mediated
by DA D1 or D2 receptor blockade in the BLA. I took advantage of the previously
established opiate reward blocking effect of the effective dose of the D1 antagonist
(SCH23390, 1.0pg/0.5pl), and co-administered a cAMP activator (see methods) to
determine if counteracting the hypothesized effects of intra-BLA D1 blockade (cAMP
inhibition) would rescue our previously observed blockade of opiate reward encoding, in
opiate naive rats (see methods). I found that indeed, activation of cAMP levels within the
BLA could effectively reverse the behavioural effects of BLA D1 receptor blockade on
opiate reward encoding (Fig. 14). A two way ANOVA showed a significant interaction
between group (intra-BLA SCH23390 alone and co-administration) and treatment (saline
vs. morphine) on times spent in saline versus morphine paired environment ( F (1, 29) =
14.69, p < 0.01, Fig. 14A). Post hoc comparisons revealed that intra-BLA D1 antagonist
treated opiate-naive rats failed to show a significant CPP for a suprathreshold dose
(5mg/kg, i.p.) of morphine (n= 7, p > 0.05). In contrast, when we administered a cAMP
activator (Sp-cAMP, 0.5pg/0.5pl) before D1 antagonist (SCH23390, 1.0pg/0.5pl)
treatment in the BLA, opiate naïve rats displayed a strong preference for the morphinepaired environment (n = 8, p < 0.01, Fig. 14A). Also, relative to animals receiving intraBLA SCH23390 alone, animals that received co-
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Figure 14
Effects of intra-BLA cAMP modulation on D1 or D2 receptor mediated blockade of
opiate reward in opiate-na’ive versus opiate-dependent and withdrawn states

A For comparison purposes, the left bar graph was taken from our previous experiment
using the D1 antagonist (SCH23390) versus suprathreshold dose of morphine (5mg/kg).
Opiate-naive rats did not show a positive CPP, whereas naïve rats that were treated with
co-administration of cAMP

activator (Sp-cAMP,

0.5pg/0.5pl)

and

SCH23390

(1.0pg/0.5pl) showed a CPP for morphine paired environment.

B For comparison purposes, the left bar graph was taken from a previous experiment for
the D2 antagonist (Eticlopride) versus a supra-threshold dose of morphine (5mg/kg) to be
used as a control, and these dependent (HDW) rats failed to show a positive CPP,
whereas naive rats that were treated with co-administration of cAMP inhibitor (Rp-cAMP,
0.5pg/0.5|il) and Eticlopride (1.0pg/0.5pl) demonstrated a CPP for morphine paired
environment.
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inistration of SCH23390 and Sp-cAMP in the BLA spent significantly more time in
morphine paired environments (n=8 , p< 0.05). These results demonstrate that
pharmacologically increasing cAMP level in the BLA prevents the blocking effect
mediated by D1 receptor blockade and rescues the morphine CPP in opiate-naive rats.

Next, I repeated these experiments in the context of intra-BLA D2 receptor
blockade. Again, we took advantage of the previously established opiate reward blocking
effect of the effective dose of the D2 antagonist (eticlopride, 1.0pg/0.5pl), and co
administered a cAMP inhibitor (see methods) to determine if counteracting the
hypothesized effects of intra-BLA D2 blockade (cAMP activation) would rescue our
previously observed blockade of opiate reward encoding, in opiate dependent and
withdrawn rats (see methods). I found that indeed, inhibition of cAMP levels within the
BLA could effectively reverse the behavioural effects of BLA D2 receptor blockade on
opiate reward encoding (Fig. 14B). A two-way ANOVA revealed a significant main
effect of treatment (saline vs. morphine) on the time spent on saline vs. morphine-paired
environments (F (1, 29) = 4.67, p < 0.05). Post hoc comparison demonstrated that opiatedependents rats treated with intra-BLA Eticlopride (1.0pg/0.5pl) did not show a CPP for
a suprathreshold dose of morphine (5mg/kg, i.p., n = 7, p > 0.05). However, dependent
rats treated with the intra-BLA cAMP inhibitor (Rp-cAMP, 0.5pg/0.5pl) prior to D2
antagonist (Eticlopride, 1.0pg/0.5pl) treatment, demonstrates a significant place
preference for morphine-paired environment (n = 8 , p < 0.05, Fig. 14B). Thus similar to
the effects reported with intra-BLA D1 blockade, inhibition of intra-BLA cAMP levels
was able to functionally reverse the effects of intra-BLA D2 receptor blockade on opiate
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reward encoding, in the opiate dependent and withdrawn state. This demonstrates that the
D1 or D2 mediated block of opiate reward encoding is closely linked to D1 or D2
mediated modulation of downstream cAMP levels, as counteracting cAMP levels within
the BLA can effectively reverse the behavioural effects of either intra-BLA D1 or D2
receptor blockade, in specific opiate exposure states.

Pharmacological modulation of intra-BLA cAMP levels reverses the reward
potentiating effects of intra-BLA D1 or D2 receptor activation
Previously, I have shown that when animals were given a sub-reward threshold
dose of morphine (0.05mg/kg, i.p.), intra-BLA administration of a D1 agonist was able to
potentiate the rewarding effects of morphine as measured in our CPP procedure only in
opiate-naïve rats (Fig. 12A). Conversely, intra-BLA administration of the D2 agonist was
able to do so only in opiate-dependent and withdrawn rats (Fig. 12B). If manipulation of
intra-BLA cAMP levels can rescue D1/D2 receptor antagonist-mediated blockade of
reward memory encoding (Fig. 14), I predicted that similarly modulating cAMP levels in
the BLA would block the opiate reward potentiating effects of intra-BLA D1/D2 receptor
activation.

My predictions for the following studies were functionally opposite to those of the
previous series of experiments (examining the effects of intra-BLA D1/D2 receptor
blockade). That is, I have attempted to block the effects of the D1 agonist (which
normally would be expected to potentiate cAMP levels) with a cAMP inhibitor.
Conversely, I have attempted to block the reward potentiating effects of the D2 agonist
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(which normally would be expected to inhibit cAMP levels) with a cAMP inhibitor. First,
comparing the effects of the intra-BLA D1 agonist alone at our previously established
effective dose (SKF81297, 1.0pg/0.5pl) or a group receiving intra-BLA pretreatment
with a cAMP inhibitor, versus a subthreshold (0.05mg/kg) dose of systemic morphine,
demonstrated that inhibition of cAMP does indeed block the opiate reward potentiating
effects of intra-BLA D1 receptor activation. A two-way ANOVA revealed a significant
main effect of treatment (systemic saline vs. morphine) on times spent in saline vs.
morphine-paired environments (F (i>29) = 8.70, p < 0.01, Fig. 15A). Post hoc analyses
showed that opiate-naive rats receiving the intra-BLA D1 agonist (SKF 81297,
1.0pg/0.5|il) alone, followed by a subthreshold dose of morphine (0.05mg/kg, i.p.)
demonstrated a CPP for morphine-paired environments (n = 8, p < 0.01; Fig. 15A).
However, in the group pre-treated with the cAMP inhibitor (Rp-cAMP, 0.5pg/0.5pl)
prior to administration of the D1 agonist (SKF81297, 1.0pg/0.5pl), no CPP was
demonstrated (n = 7, p > 0.05).

I next repeated this study using the previously established effective dose of the D2
receptor agonist (Quinpirole, 1.0pg/0.5pl) in opiate-dependent and withdrawn rats. A two
way ANOVA revealed a significant interaction between group (intra-BLA SKF81297
alone and co-administration and treatment (saline vs. morphine) on times spent in saline
vs. morphine-paired environments (F (i,

27)

= 13.21, p < 0.01, Fig. 15B). Post-hoc

analyses showed that opiate dependent rats receiving intra-BLA D2 agonist alone
(Quinpirole, 1.0pg/0.5pl) followed by a subthreshold dose of morphine (0.05mg/kg, i.p.)
displayed a significant CPP for morphine-paired environments (n = 8, p < 0.01,).
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Figure 15
Effects of intra-BLA cAMP modulation on D1 or D2 receptor mediated potentiation
of opiate reward in opiate-naive versus opiate-dependent and withdrawn states

A. For comparison purposes, the left bar graph shows effects of the D1 agonist
(SKF81297) versus a subthreshold (0.05mg/kg, i.p.) dose of morphine, demonstrating
that intra-BLA D1 receptor activation potentiates sub-reward threshold morphine CPP.
When opiate-naive rats were treated with intra-BLA co-administration of the cAMP
inhibitor (Rp-cAMP, 0.5pg/0.5|il) and SKF81297 (1.0pg/0.5|il), the reward potentiating
effects of intra-BLA D1 receptor activation were abolished.

B. For comparison purposes, the left bar graph shows the opiate reward potentiating
effects of the intra-BLA D2 agonist (Quinpirole) versus a subthreshold (0.05mg/kg, i.p.)
dose of morphine. When we treated dependent (HDW) rats with co-administration of the
cAMP inhibitor (Rp-cAMP, 0.5pg/0.5pl) and SKF81297 (1.0pg/0.5pl) into the BLA, the
opiate reward potentiating effects of BLA D2 receptor activation were abolished.
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However, in opiate dependent rats pre-treated with the intra-BLA cAMP activator (SpcAMP, 0.5|ig/0.5pl) prior to D2 agonist administration (Quinpirole, 1.0pg/0.5pl), this
opiate reward potentiation was blocked, demonstrating that counteracting the predicted
effects of cAMP levels via D2 receptor activation, can block the behavioural effect of
opiate reward encoding amplification (n = 7, p > 0.05, Fig. 15B).

Together, these studies have demonstrated a critical role for D1 and D2 receptor
mediated modulation of cAMP levels within the BLA during the processing of opiate
related reward memory.
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Chapter 4 Discussion
Opiate class drugs activate the mesocorticolimbic system, and subsequently
increase DA concentration and activate DA receptors in various brain regions, including
the NAcc and the amygdala (Di Chiara, 1999; Sell 1997, 1999; Volkow, 2009). The role
of DA transmission during primary opiate reward processing appears to depend on the
prior opiate exposure history of the organism. Thus, the primary rewarding effects of
opiates can be processed via DA-independent neural pathways in previously opiate-naive
animals, however, once opiate dependent and withdrawal state has developed, the
rewarding effects are dependent upon DAergic neural pathways (Laviolette et al. 2004;
Laviolette et al., 2002). While DA transmission in the NAcc followed by opiate exposure
has been examined closely, little is known regarding the role of DA transmission from the
VTA to the BLA in the context of opiate reward processing. In addition, while
considerable research has characterized the neural systems controlling primary opiate
reward signalling during different stages of opiate exposure, very little is known
regarding which specific neural systems are essential for the associative encoding of
opiate-reward related information. More importantly, it is presently not known if the
same neural substrates and/or neuropharmacological systems are involved in associative
opiate reward learning in the drug naive state, versus the drug dependent and withdrawn
state. Given that the BLA is implicated in forming conditioned associations between
sensory stimuli and motivationally salient events (LeDoux, 2000; McGaugh, 2002) and is
strongly modulated by DAergic signaling, the goal of my thesis was to elucidate the role
of DA transmission via DA receptor subtypes within the BLA during the encoding of
associative opiate reward learning and memory.
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Our results demonstrated that DA receptor transmission in the BLA strongly
modulates the associative opiate reward encoding process in both opiate naive and opiate
dependent states. Surprisingly, we observed a functional double dissociation between the
roles of DA D1 versus D2 receptor signalling as a function of opiate exposure state. Thus,
while blockade or activation of DA D1 receptors within the BLA blocked or potentiated,
respectively the rewarding effects of opiates in previously opiate naive animals, once
animals were made opiate dependent and in a state of withdrawal, these same modulatory
effects of DA transmission were only evident with blockade or activation of the DA D2
receptor subtype. We have also identified that the potentiating effect via DA D1 or D2
receptor activation requires a presumptive BLA GLUT projection to the NAcc shell
subregion. In addition, our findings indicate that the effects of DA receptor transmission
on opiate reward encoding in the BLA are dependent upon downstream secondary
messenger cAMP activity, because modulation of cAMP levels within the BLA
counteracts the modulatory actions of DA receptor transmission on opiate reward
encoding regardless of opiate exposure state.

4.1 The Effects of intra-BLA D1 and D2 Receptor Blockade on
Associative Opiate Reward Encoding

4.1.1 DA D1 and D2 Type Receptor Transmission within the BLA Differentially
Modulates Systemic Opiate Reward Encoding as a Function of Opiate Exposure
State
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Comparing the effects of the DA D1 versus D2 receptor manipulation in the BLA
in opiate naive and opiate dependent rats, we observed a double dissociation for the
functional roles of DA D1 and D2 receptors as a function of opiate exposure state. Our
result demonstrate that pharmacological blockade of DA D1 receptors within the BLA
blocks morphine reward encoding in opiate naive rats, but not opiate dependent and
withdrawn rats, over an order of magnitude dose range. In contrast, blockade of DA D2
receptors within the BLA, dose-dependently blocked the encoding of associative
morphine reward memory in opiate dependent rats, but not in opiate naïve rats. These
results indicate that in opiate naïve rats, the reward encoding process requires DA D1
receptor transmission within the BLA, but not D2 receptor transmission. However, in
opiate dependent rats, the reward encoding process requires DA D2 but not D1 receptor
transmission within the BLA. To our knowledge, these results are the first demonstration
for an opiate-exposure related switch in reward-related memory encoding between a D1
versus a D2 receptor substrate, in the context of opiate-related reward memory.

In order to explain the functional role of the BLA and the DA D1/D2 receptor
double dissociation phenomenon, our theoretical framework focused on the DA
projection pathway from the VTA to the BLA and how specific signalling through D1
versus D2 receptor populations may theoretically modulate opiate-related motivational
information being transmitted from the VTA to the BLA. As shown in our proposed
model (Fig. 1), opiate class drugs indirectly amplify the VTA DA output by inhibiting
GABAergic intemeurons that normally provided feedforward inhibition to the VTA A10
DAergic neurons (Wise 1996; Kalivas 2002; Fig. 1). Once these VTA DA neurons are
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activated by opiates, enhanced DA signals representing the motivational salience of
morphine is sent to the BLA, where we hypothesize that the initial associative reward
memory encoding takes place (Brinley-Reed and McDonald, 1999). The BLA contains
well characterized populations of intrinsic, inhibitory intemeurons and pyramidal
projection neurons. Within the BLA, GABAergic intemeurons modulate the activity of
projection neurons and the intemeurons are under GLUT influence coming from the PFC
(Fig. 2). Previous research using extracellular recordings demonstrate that the PFC inputs
excite GABAergic intemeurons of the BLA under normal circumstances, suggesting a
“braking” mechanism by which the PFC GLUT projections regulate BLA output and
suppresses BLA-mediated brain functions (Rosenkranz and Grace, 2001). In contrast,
inputs from sensory cortical regions to the BLA drive BLA-mediated functions instead of
suppressing them (Szinyei et al., 2000; Rosenkranz and Grace, 2002). However, in
situations where an emotional response is important, the PFC-mediated suppression must
be lifted to facilitate amygdala functions (Marowsky et al., 2005). Work done by
Rosenkranz and Grace (1999) has shown that when an affective stimulus is present,
causing DA being released into the BLA, the sensory input is strongly potentiated while
the PFC-mediated inhibition is dampened. It is possible that DA transmission in the BLA
modulates the afferent PFC and sensory inputs, shifting the BLA to a disinhibited state.
In this case, increased BLA projection neuron activity may initiate the associative reward
learning process. Other than reward learning, there is evidence for depressed amygdalarelated behaviour such as fear learning due to DA transmission blockade (Lamont and
Kokkinidis, 1998; Nader and LeDoux, 1999). Experiments conducted by Kroner and
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colleagues (2005) also indicate that the DAergic modulation of learned associations is the
result of direct action of DA on BLA neurons during affective learning.

In my experiments, pharmacological blockade of DA transmission in the BLA
blocked the acquisition of morphine reward in both opiate naïve and opiate dependent
states, but through distinct DA receptor subtype populations. In our model, we propose
that the baseline state of BLA activity (in the absence of affective or motivational events)
would involve ongoing tonic activity of feedforward inhibitory GABAergic input to BLA
projection neurons and/or tonic input from the PFC-dependent descending GLUT inputs
acting on GABAergic neurons serving as a further 'brake' on emotional associative
encoding in the BLA (Rosenkranz & Grace, 2001). However, opiates, representing a
highly motivationally salient stimulus in the VTA, would essentially flood the BLA with
DA. In my model, blockade of DA D1 receptors would prevent DA-mediated inhibition
of GABAergic intemeurons (which normally would serve to remove this inhibition and
activate BLA projection neuron activity; Fig. 2). Thus, D1 antagonist blockade (at least
in the opiate naive state) would effectively block incoming opiate-related motivational
information from the VTA to the BLA, preventing the encoding of opiate associative
reward memory, as demonstrated by our place conditioning results. Similarly, blockade
of D2 receptors, which we hypothesize to be preferentially localized on presynaptic PFC
GLUT terminals projecting onto GABAergic intemeurons (to be discussed in detail
presently; Fig. 2), would remove DA-mediated inhibition of these excitatory GLUT
inputs and increase GABA intemeuron activity, again blocking DA-related activation of
BLA projection neurons.
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The above evidence supports the role of BLA as a site for associative opiate
reward learning, but does not explain the double dissociation phenomenon where separate
DA receptor in the BLA controls the opiate reward encoding in different opiate exposure
state. As mentioned previously, DA signaling takes place via Dl-like or D2-like receptors.
As I have hypothesized in Fig. 1, in the presence of opiate class drugs, DA outflow from
the VTA increases and activates DA D1 and D2-like receptors within the BLA. Previous
electrophysiological research has shown that both types of DA receptor may contribute to
the increased excitability of BLA projection neurons and the stimulation of these DA
receptors modulates afferent activity, and may facilitate the salience of emotionally
relevant stimuli (Rosenkranz and Grace, 1999). As shown in Figure 2, the DA D1
receptors within the BLA have been reported to be directly associated with local
GABAergic intemeurons and modulate PFC GLUT transmission via a postsynaptic
mechanism (Gabbott et al., 2005; Rosenkranz and Grace, 2002). On the other hand, the
DA D2 receptors are reportedly associated with presynaptic terminals originating from
the PFC, and the activation of D1 and/or D2 receptors increases the activity of projection
neurons and promotes plasticity within the BLA, presumably by decreasing the actions of
excitatory GLUT inputs onto the local GABAergic intemeurons (Pinto and Sesack, 2008).
Therefore, the blockade of either type of DA receptors should be able to decrease the
activity of BLA projection neurons by increasing the intrinsic inhibitory feedback.
Furthermore, anatomical mapping studies by Gaspar and colleagues (1995) have reported
the presence of D2 receptor mRNA in PFC projection neurons, suggesting that the DA
D2 receptors are directly influenced by neuronal activities within the PFC. As previously
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indicated, the PFC is critical for processing drug-related associative information in long
term drug abusers. Evidence from imaging studies has demonstrated the correlation
between PFC activation and opiate craving memories in opiate dependent subjects
(Daglish et al., 2001; Sell et al., 1999, 2000). Decreased PFC activity related to impulsive
behaviour is also observed in heroin addicts (Lee et al., 2005). In my proposed model,
one possibility is that in animals chronically dependent and in withdrawal from opiates,
the transmission of opiate-related motivational information from the VTA switches to a
D2 receptor-dependent mechanism in the BLA, associated with presynaptic GLUT inputs
from the PFC (Fig. 2). In this case, chronic opiate exposure may lead to dysrégulation in
neuronal activities within the PFC such that in the chronic drug state, opiate-related
information preferentially triggers PFC neuronal activity (perhaps by increasing DAergic
outputs from the VTA to the PFC, in addition to our proposed VTA-BLA pathway). In
this case, animals being conditioned in a state of opiate dependence and withdrawal may
experience a shift towards PFC-dependent opiate motivational processing, which in turn,
may render descending PFC to BLA projections (and their associated D2 receptors) more
critical for associative opiate reward processing in the dependent and withdrawn state.
That is, animals in a state of opiate withdrawal would be more sensitive to intra-BLA D2
receptor blockade relative to D1 receptor transmission, ultimately leading to the observed
double dissociation phenomenon.

In addition, neuronal alterations in the VTA and the BLA could also be
contributing factors. As discussed previously, the VTA serves as a critical site for the
primary rewarding effects of opiates through actions on p-opioid receptors, which in turn
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modulate DA signaling to the BLA, amongst other neural target regions (Fig. 1). Thus,
while opiate class drugs modulate VTA DA neuron activity acutely (Fig. 1), over the
time course of chronic opiate exposure, morphological and functional changes take place
both at the level of VTA p-opioid receptors, and within VTA DA neurons themselves,
leading to a decrease in the firing rate of DA neurons in the VTA (Liao et al., 2005;
Volkow et al., 2002). Moreover, reward-related cues significantly increase the
internalization of p-opioid receptor (Balfour et al., 2004) These modifications are
indicative of neuroadaptive processes in the VTA and it may contribute to the functional
shift of DA D1 and D2 receptor in the BLA. In opiate naïve state, the DA signalling
between VTA and BLA may be D1 receptor-selective, and these receptors are thus
overstimulated and perhaps down-regulated. Indeed, previous evidence has shown that
prolonged DA stimulation causes compensatory cellular adaptations, such as altered
sensitivity to neurotransmitter and internalization of the DA D1 receptors on postsynaptic DA receptor substrates (Berke and Hyman, 2000). Thus, one possibility for our
observed de-sensitization to the effects of intra-BLA D1 receptor blockade during the
opiate dependent and withdrawn state, may be the result of altered VTA-BLA DA firing
activity, resulting in intra-BLA D1 receptors internalization on GABAergic intemeurons,
which theoretically, would render pharmacological manipulations of BLA D1 receptors
ineffective in blocking the encoding of opiate reward memory, as I observed in the opiate
naïve state. Simultaneously, such a shift between D1 versus D2 receptor viability across
opiate exposure states may explain why D2 receptor substrates become necessary during
the opiate dependent and withdrawn state, whereas D1 receptor signalling would
presumably predominate in the opiate naïve condition (Fig. 2). Finally, given that the
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present results show preferential D1 receptor sensitivity in opiate naive condition, a
further possible explanation may come from anatomical studies demonstrating relatively
greater concentrations of D1 versus D2 receptors in the BLA (Missale et al., 1998;
Weiner et al., 1991) which would further suggest preferential sensitivity to D1 receptor
manipulations, at least in the opiate naive condition.

While my studies did not focus upon the adjacent central nucleus of the amygdale
(CeA), one previous report using intra-CeA microinfusions of a D1 receptor antagonist
found a ‘partial’ block of opiate reward encoding, using a biased version of the CPP
procedure (Zarrindast et al., 2003). While it is difficult to directly compare the results due
to procedural differences, this report provides convergent evidence for a role for intra
amygdala D1 receptor transmission as being important for opiate reward memory
encoding. In addition, DA receptor antagonism in the BLA blocks fear potentiated startle
and cocaine reward (Lamount and Kokkinidis, 1998; Berglind et al., 2006). Although the
above described studies are not directly comparable to my methodologies, they provide
converging evidence linking the importance of DA receptor transmission within the BLA
with the encoding of emotionally and motivationally salient associative information.

While additional studies are required to elucidate the role of PFC and VTA
influence on the BLA-mediated activities, the present result suggests that DA receptor
transmission in the BLA is closely involved in the associative opiate reward memory
encoding process as a function of opiate exposure state, and chronic opiate exposure
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switches the functional balance of intra-BLA DA transmission from a D1-dependent
substrate to a D2-dependent substrate.

4.1.2 Opiate Reward Signals from the VTA are encoded by the DA D1 and D2
Receptor Transmission within the BLA
As I described in Fig. 1, most opiate class drugs including morphine and heroin
produce their acute physiological effects by binding to p-opioid receptors located in the
VTA and thus indirectly activate the mesocorticolimbic DA system (Wise, 1989, 1996).
Studies have shown that opioid receptor blockade in the VTA disrupts morphine induced
CPP, suggesting that the VTA serves as the critical brain region for the processing the
primary reinforcing effects of opiates (McBride et al., 1999; Olmstead and Franklin,
1997). In the present study, we performed a series of intra-VTA microinfusion studies
aimed at determining whether morphine motivational signalling directly from the VTA to
the BLA is modulated by intra-BLA D1/D2 receptors. Given our proposed model in Fig.
1, these studies were crucial for establishing the importance of the VTA-BLA circuit in
our previously observed effects using only systemic morphine administration. Consistent
with our first series of experiments using systemic morphine, we again observed a double
dissociation phenomenon of intra-BLA D1 versus D2 receptor transmission as a function
of opiate exposure state. Thus, in the opiate naïve state, the acquisition of intra-VTA
associative morphine reward memory requires D1 receptor transmission in the BLA,
whereas D2 receptor transmission is required only in the opiate dependent state.
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These results complement our previous findings with systemic morphine and
suggest that both systemic and intra-VTA morphine reward signalling are critically
modulated by D1 or D2 receptor transmission directly within the BLA, as a function of
opiate exposure state. In either case, we propose that the morphine reward information
represented by amplified DA transmission is coming from the VTA and the associative
reward memory is also encoded by the same brain region, the BLA. Moreover, my
findings further confirm that the VTA plays an important role in the acquisition of opiate
reward as the primary reward processing site consistent both with previously discussed
research, and with our overall theoretical model proposed in Figure. 1.

4.1.3 Functional Plasticity of the BLA DA D1/D2 Switching Mechanism
I have thus far determined a functional switching mechanism between the D1 and
D2 receptors in the BLA at two distinct phases of opiate exposure. However, an
important question in addiction research concerns the plasticity of neural mechanisms and
neuroadaptations that occur following chronic drug exposure. In other words, does the
development of drug dependence represent a transition to a static, chronic disease-like
state, or is addiction more accurately described as a plastic neural process, that can be
reversed once recovery from dependence has taken place? In terms of opiate-related
addiction, previous work by Laviolette et al. (2004) demonstrated a plastic opiateaddiction switching mechanism in the rodent VTA that dependent upon a functional
alteration in GABAa receptor transmission. Although the details of this work are beyond
the scope of this discussion, the general conclusion from these studies was that opiate
addiction, and the switch between a non-DA versus a DA-dependent motivational reward
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pathway, could be switched back to a functionally ‘drug-naive’ state, either once animals
had recovered from chronic opiate exposure, or by pharmacologically reversing the
molecular mechanism controlling the switch in VTA opiate reward transmission.
However, the potential implications for these results in terms of amygdala-mediated
modulation of opiate associative memory encoding are not understood.

Given our observation of a functional switch in intra-BLA D1 versus D2 receptor
transmission as a function of opiate state in the present study, I examined whether this
BLA-dependent mechanism may represent a permanent change in opiate-related reward
memory encoding, or whether this observed mechanism may be reversible, once recovery
from chronic opiate exposure had taken place. My results showed that after recovery
from our chronic opiate exposure protocol, previously opiate dependent rats demonstrated
the same behavioural outcome as rats in opiate naive state, suggesting that the DA
receptor switching mechanism in the BLA is a dynamic response to opiate exposure, and
the original state is restored after recovering from opiates. One possible cause is that the
synaptic plasticity within the mesocorticolimbic DA system dynamically changes in
response to opiate exposure. For example, as previously discussed, neuroplastic processes
allow neurons and/or neural circuits to adjust their functional activity according to new
situations or changes in the environment and studies have demonstrated that many brain
areas in the mesocorticolimbic system are capable of such neuroplastic changes, such as
the amygdala, NAcc, PFC and VTA (Bissiere et al., 2003; Kalivas, 2002; Koob, 2010;
McGaugh, 2002).
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From a theoretical perspective, several drug addiction models have attempted to
model neuroplasticity processes as a result of chronic drug exposure. For example, Koob
(2009) has proposed that drug addiction represents an “allostatic process” defined as
“stability through change”. While early drug exposure activates reward and reinforcement
neural systems, with continued exposure, Koob proposed that ‘opponent’ neural systems
begin to dominate, characterized by the aversiveness of drug withdrawal, leading to a
chronic ‘downward spiral’ of escalating drug use to counteract the negative psychological
process of withdrawal. Although under normal circumstances this proposed homeostatic
process serves as a mechanism allowing the organism to rapidly respond to changing
environmental circumstances, it contributes to the pathology of drug addiction. With
repeated drug use, the brain attempts to maintain stability through cellular and
neurocircuitry changes but at a price, worsening the negative withdrawal state that leads
to compulsive drug-seeking, unless adequate time is available to stop this response (Koob
and LeMoal, 2001). In contrast to such a ‘homeostatic’ drug addiction model, in the
present study, a 7-day recovery period was sufficient to stop the any proposed neural
allostatic response initiated by the heroin treatment and repeated withdrawal.

Thus, rather than being indicative of a chronic and static switch within the BLA
between D1 versus D2 receptor transmission, our results, similar to those previously
discussed in the context of the VTA (Laviolette et al., 2004) suggests a more plastic,
transient switch that can be reversed once recovery from dependence and withdrawal has
taken place. Nevertheless, certainly chronic drug exposure can sensitize the organism to
subsequent associative drug-memory cues, possibly leading to relapse to addiction even
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years after recovery from dependence. While my results suggest a plastic DA D1/D2
switching mechanism within the BLA as a function of opiate exposure, other neural
systems, such as the PFC, may be ultimately responsible for the encoding of chronic,
long-term associative opiate-related reward memories that can trigger relapse during
future drug-related associative memory recall. Future studies are required to more fully
examine these possibilities.

4.2 The effects of D1 or D2 Receptor Activation in the BLA: Modulation
of Opiate Reward Amplitude
As presented above, D1 and D2 receptor intra-BLA antagonist studies have
demonstrated that depending on the state of opiate exposure, D1 and D2 receptor
transmission in the BLA differentially controls the encoding of associative opiate reward
memory. Given these findings, and based upon the hypothesized arrangement of D1
versus D2 receptors within the BLA (Fig. 2) I predicted that activation of D1 or D2
receptors within the BLA may produce the behaviourally opposite result from that of
receptor antagonism: namely, a potentiation of opiate reward magnitude. For example,
D1 receptor activation would be predicted to inhibit the tonic activity of intrinsic,
inhibitory intemeurons within the BLA, thus amplifying the activity of BLA projection
neurons to reward-relevant neural targets, such as the PFC or NAcc. Activation of presynaptically located D2 receptors would be predicted to inhibit excitatory GLUT inputs
onto the intrinsic inhibitory GABAergic neurons, again leading to decreased inhibition on
feedforward GABAergic neurons in the BLA, and the potentiation of BLA projection
neuron outputs to reward-related neural targets (Figs. 1 and 2). If this is the case, I
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predict that the D1 and D2 agonists may likely act in a similar fashion, following the
dissociation between the opiate naive and opiate dependent state. I therefore conducted a
series of agonist studies to examine the effect of D1 vs. D2 receptor agonist in the BLA
on a sub-reward threshold dose of morphine (0.05mg/kg; i.p.), which, as our lab has
previously reported (Bishop et al., 2010) does not normally induce a place preference.

4.2.1 Dopamine D1 or D2 Receptor Activation in the BLA Potentiates Opiate
Reward Signaling as a Function of Opiate Exposure State via a GLUT Projection
from the BLA to the Shell Subregion of the NAcc
In the present study, I found that DA D1 or D2 receptor agonist application in the
BLA strongly potentiated the rewarding effects of a normally sub-reward threshold dose
of systemic morphine (0.05 mg/kg; i.p.), as measured in our CPP conditioning procedure.
Interestingly, I observed the same functional dissociation between DA D1 versus D2
receptor transmission as a function of opiate exposure state, with intra-BLA D1 activation
potentiating morphine reward encoding in the opiate naive state exclusively, and intraBLA D2 receptor activation only potentiating morphine reward signals during the opiate
dependent and withdrawn state. Thus, these findings are in agreement with the results of
my intra-BLA DA receptor antagonist studies and further confirm the function of BLA as
an opiate reward encoding site, once again demonstrating a functional segregation of D1
vs. D2 receptor populations within the BLA in separate opiate exposure states.

In terms of the effects of DA receptor agonist activation within the BLA, our
previously described model (Fig. 1 and 2) may also explain our behavioural results. As
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noted previously, the PFC sends excitatory GLUT inputs to the GABAergic intemeurons
in the BLA and indirectly inhibits the output of pyramidal neurons to other brain area,
especially the NAcc (Fig. 3). As indicated in Figure 2, the D1 receptors within the BLA
are closely associated with GABAergic intemeurons and they modulate PFC GLUT
influence via a postsynaptic mechanism. On the contrary, the D2 receptors, being
associated with the PFC projection neurons, are primarily expressed at the presynaptic
level (Pinto and Sesack, 2008). One possibility is that when DA D1 or D2 receptor
agonists are administered, they further amplify the DA release by a subthreshold
morphine reward and thus increase BLA projection neuron activity by lifting the PFCmediated inhibition. As a result, BLA-mediated associative encoding events that are
processed by the projection neurons are enhanced, providing a possible explanation for
our observed behavioural potentiation of normally sub-reward threshold morphine CPP
encoding.

Given that the morphine reward potentiating effects of D1 or D2 receptor
activation followed the same functional boundary between the opiate naive versus
dependent and withdrawn states as observed in our DA receptor antagonist studies, there
are several interesting possibilities that may account for this observed intra-BLA switch
from a D1-mediated to a D2-mediated DA receptor reward encoding substrate. For
example, as previously discussed in the context of our DA receptor antagonist studies,
one possibility is that DA transmission within the BLA preferentially activates D1
receptor populations, over D2 populations, as proposed in Figure. 16. In this case,
activation of D1 receptors preferentially localized to intrinsic inhibitory intemeurons
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Figure 16
Proposed mechanism for functional switch of BLA D1 versus D2 receptor activation
as a function of opiate exposure state

A. In opiate naive state, activation of D1 receptors preferentially localized to intrinsic
inhibitory intemeurons inhibits these neurons and removes feedforward inhibition on the
BLA projection neurons, thereby amplifies the opiate motivational signal arising from
VTA inputs and potentiates a CPP for subthreshold morphine reward. The GLUT outputs
from BLA projection neurons to the NAcc may be responsible for the behavioural
encoding of these reward potentiating effects of D1 versus D2 activation within the BLA.

B. In opiate dependent and withdrawn state, we propose a functional shift in sensitivity
from the D1 receptor population to the D2 receptor population. Activation of inhibitory
D2 receptors associated with presynaptic GLUT inputs onto BLA GABAergic neurons
removes excitatory influences upon BLA inhibitory intemeurons, thereby removing tonic
inhibition on the BLA projection neurons and potentially amplifying opiate reward
signals arising from the VTA. The GLUT outputs from BLA to the NAcc are critically
involved in the behavioural outcome of such reward signal amplification.
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would be expected to inhibit these neurons, removing feedforward inhibition to the BLA
projection neurons and thereby amplifying the opiate motivational signal arising from
VTA inputs (Fig. 16A). In contrast, once opiate dependence and withdrawal are present,
we propose a functional shift in sensitivity from the D1 receptor population to the D2
receptor population as described previously. In this case, activation of inhibitory D2
receptors associated with presynaptic GLUT inputs onto BLA GABAergic neurons,
would essentially remove excitatory influences upon BLA inhibitory intemeurons,
thereby removing tonic inhibition on the BLA projection neurons and potentially
amplifying normally sub-reward threshold opiate reward signals arising from the VTA
(Fig. 16B). However, a critical question concerns which output from the BLA may be
responsible for signalling a potentiated associative opiate reward memory, into its
behavioural output? As described in our general model in Fig. 1, we hypothesized that
GLUT outputs from BLA projection neurons to the NAcc may be responsible for the
behavioural encoding of these reward potentiating effects of D1 versus D2 activation
within the BLA.

As demonstrated in our model (Fig. 3), the NAcc receives convergent inputs from
VTA, PFC and BLA. In terms of our observed effects of intra-BLA D1 or D2 receptor
activation, we chose to focus specifically on the potential role of GLUT outputs from the
BLA, converging on the shell sub-region of the NAcc, for several reasons. First, previous
research has shown that the association of previously neutral sensory conditioning stimuli
with primary reward effects during conditioned reinforcement learning is dependent on
functional interactions between the BLA and the NAcc (Cador et al., 1991; Robins and
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Everitt, 1992). Within the NAcc, the shell sub-region has been implicated as the critical
site for DA-dependent reward processing and it is closely involved in incentive
motivational learning (Di chiara, 2002; Di Chiara et al., 2004). If GLUT output from the
BLA to the NAcc shell is indeed a critical link for the observed reward potentiating
effects of intra-BLA DA DI or D2 activation, I hypothesized that blockade of NMD A
receptors within the shell may prevent our observed morphine reward potentiation
following intra-BLA DI or D2 activation (see methods). Again using quadruple
cannulations and combining bilateral microinfusions of the NMDA receptor antagonist,
AP-5 into the NAcc shell immediately prior to intra-BLA DI or D2 agonist
administration, was able to block our observed potentiation in associative opiate reward
learning. In addition, this dose of intra-NAcc shell AP-5 by itself did not block the
encoding of a just supra-threshold dose of systemic morphine, demonstrating that intraNAcc shell NMDA receptor blockade was not simply producing a non-specific block of
associative reward learning.

The importance of BLA GLUT influence on the NAcc is well demonstrated in
work done by Floresco and colleagues (1998), which showed that stimulation of GLUT
inputs from the BLA to the NAcc increases mesoaccumben DA efflux and enhances
NAcc neuron firing, which in turn facilitates approach behaviour towards reward-related
stimuli. They also propose that changes in NAcc DA levels following reward-related
stimuli maybe mediated by the BLA. Our findings are further supported by their later
work, which shows that NMDA antagonists in the NAcc abolishes the potentiation of
BLA-evoked spiking activity, and NMDA receptor activation is essential for the
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induction and maintenance of this DAergic potentiating effect within the NAcc (Floresco
et al., 2001). This evidence, in combination with our reported effects, while not ruling out
potential effects of projections from many others brain regions to the NAcc, strongly
suggest that BLA DA receptor mediated morphine reward potentiation requires GLUT
projections from the BLA to the NAcc shell. Nevertheless, future studies will be required
to examine the possible involvement of the ‘core’ sub-region of the NAcc, to determine if
BLA GLUT projections this subregion may also play a role in these effects. In addition, it
will be interesting to examine other GLUT receptor subtypes in order to see if this GLUT
signalling mechanism relies exclusively on NMDA receptor transmission, or may involve
additional GLUT receptor subtypes, such as AMP A, or metabotropic GLUT receptors.

4.3 Molecular Mechanisms Underlying D1 versus D2 Receptor
Modulation of Opiate Reward Encoding: The Role of cAMP
The behavioural pharmacological studies described thus far have revealed several
novel insights into the functional roles of DA D1 versus D2 receptor signalling within the
BLA during the encoding of associative opiate reward memory. However, the potential
downstream molecular events that are ultimately responsible for our observed
behavioural effects are important to identify. For example, from a clinical perspective,
drugs targeting D1 or D2 receptors (e.g. neuroleptic medications) would not likely be
appropriate targets for developing pharmacotherapies for treating opiate-related
associative memory encoding. Indeed, such drugs are likely to produce highly
undesirable side effects through direct actions on the DA receptors. Given the well
characterized ability for chronic opiate exposure to modulate cAMP levels in various
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neural regions, along with the previously described effects of D1 and D2 receptor
signalling on intracellular cAMP levels, I performed a series of experiments aimed at
determining if and how altering cAMP levels may reverse or re-produce the observed
behavioural effects of DA D1/D2 receptor activation or blockade, during the encoding of
associative opiate reward memory. As noted previously, D1 receptor activation increases
the level of the secondary messenger cAMP via Gs protein, whereas D2 receptor
activation decreases it through Gi protein interactions (Self and Nestler, 1995). This
bidirectional control of cAMP levels suggests an interesting molecular target in the
context of our behavioural pharmacology studies. I therefore predicted that the change in
cAMP levels following the action of DA on either D1 or D2 receptors may mediate the
observed functional double dissociation phenomenon, as will now be discussed.

4.3.1 The Effects of DA D1 and D2 Receptor Transmission on Opiate Reward
Encoding in the BLA are Dependent upon Downstream cAMP Activity
Given that ‘activation’ of D1 receptors normally increases cAMP levels, we
predicted that the functional effect of intra-BLA D1 ‘antagonism’ would be the inhibition
of tonic cAMP levels. In contrast, activation of D2 receptors normally would inhibit
cAMP levels and therefore the functional effects of D2 blockade would be to increase
tonic cAMP levels within the BLA. I thus tested the effects of either activators or
inhibitors of cAMP alone, or in co-administration studies with intra-BLA D1 or D2
receptor agonists or antagonists. Essentially, I predicted that the functional effects of a D1
antagonist and cAMP inhibitor would be congruent, in decreasing cAMP levels within
the BLA and blocking associative morphine reward learning in opiate naive rats. Indeed,
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intra-BLA administration of a cAMP inhibitor alone completely blocked opiate reward
learning in opiate naive rats. Similarly, I predicted that a D2 antagonist and cAMP
activator would act congruently to both increase cAMP levels and block the learning
process in opiate dependent rats. Again, I found that intra-BLA administration of a cAMP
activator alone, completely blocked opiate reward learning in opiate dependent and
withdrawn rats, similar to the effects of the intra-BLA antagonist. Although this
relationship has not previously been demonstrated directly within the amygdala, such a
functional relationship between D1/D2 receptor activation and cAMP signaling is
supported by previous studies performed in the NAcc, a site with high expression of both
DA D1 and D2 receptors. For example, cAMP inhibitors mimicked the functional effects
of a D2 agonist (Self and Nestler, 1998). Given the fact that second messenger cAMP is
downstream of DA receptors, my results would be expected. Nevertheless, they provide
compelling pharmacological control evidence for both D1 and D2 receptor mediated
modulation of cAMP levels in observed behavioural effects and demonstrate for the first
time, an important role for cAMP modulation during the encoding of associative opiate
reward memory directly in the BLA.

I then took one step further and examined whether pharmacological manipulation
of cAMP levels would counteract the effects of DA D1/D2 receptor modulation on
behavioural opiate reward encoding. The results of these studies demonstrated that
pharmacologically activating or inhibiting cAMP, respectively, I was able to rescue the
D1 and D2 receptor mediated blockade of morphine reward memory encoding in either
the opiate naive or opiate dependent states via the co-administration of a specific cAMP

Ill
modulators in these different experimental conditions. Furthermore, I found that
pharmacological inhibition of intra-BLA cAMP levels also blocked D1 receptor mediated
morphine reward potentiation in naive rats and activation of cAMP levels was capable of
blocking D2 receptor mediated reward potentiation in opiate dependent rats. These results
suggest that the effects of D1 and D2 receptor transmission on opiate reward encoding in
the BLA are dependent upon downstream cAMP activity, as modulation of cAMP can
prevent the functional effects mediated by D1/D2 BLA transmission regardless of opiate
exposure state. Moreover, because D1 and D2 receptor activity in the BLA is linked to
the cAMP pathway, the double dissociation phenomenon is likely mediated by the same
pathway. Chronic opiate exposure causes molecular adaptation in the cAMP pathway
within BLA neuronal populations, which may then contribute to the functional switch of
D1 vs. D2 receptors in the BLA from opiate naïve to opiate dependent state. Given that
these studies relied upon behavioural output alone, future studies are required to more
precisely characterize the functional relationship between cAMP signalling and our
observed dissociation in the effects of D1 or D2 receptor transmission in the BLA, across
opiate exposure states. In addition, currently available pharmacological compounds
known to modulate cAMP levels are not particularly specific to the cAMP cascade, and it
is thus possible that in the current studies, molecular pathways beyond the cAMP system
are being modulated by these compounds.

Other than the BLA, molecular adaptation in the cAMP second-messenger system
has also been reported in locus ceruleus neurons following chronic opiate exposure
(Nestler, 1992). As a result, neuronal activity of locus ceruleus is increased and this effect

112

is believed to be related to the somatic and aversive effects of opiate withdrawal. Thus,
although previous studies draw an interesting correlational link between the effects of
chronic opiate exposure and the development of opiate dependence and withdrawal, the
present experiments are the first studies we are aware of to link alterations in BLA cAMP
levels with DA receptor mediated encoding of associative opiate reward memories.
Furthermore, potential pharmacotherapies aimed at modulation of cAMP cascades may
be therapeutically useful in controlling the strength of associative opiate reward memory
encoding, and possibly diminishing the ability of opiate-related environmental cues to
trigger associative opiate reward memories linked to relapse of opiate craving. Future
studies will examine how these cAMP manipulations may modulate cue-induced opiate
memory recall as a possible way to address these remaining questions.
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Chapter 5 Conclusions and Future Directions
The results reported in this thesis are the first demonstration for a functional
D1/D2 receptor switching mechanism specifically within the amygdala. D1 and D2
receptors in the BLA can dynamically control the encoding of associative opiate reward
memory as a function of opiate exposure state. Our results provided behavioural evidence
for BLA D1 and D2 receptor activation and inactivation during morphine reward
acquisition phase and further extended the understanding of BLA as an associative
memory encoding site in the context of opiate addiction. In addition, my studies
demonstrated a critical role for cAMP activity downstream of DA D1 or D2 receptor
transmission as being critical for the encoding of associative opiate reward memory.

The results of the studies described in this thesis have revealed a novel functional
role for intra-BLA D1 and D2 receptor transmission within the BLA for the modulation
of opiate-related associative memory encoding. However, several important questions
will need to be addressed in future studies. For example, while the present experiments
were limited to behavioural pharmacological analyses, in vivo electrophysiological
recording studies of neuronal populations within the BLA, NAcc and PFC will be helpful
in determining precisely how modulation of D1 and D2 receptor transmission may alter
neuronal encoding of associative information and/or neuronal response patterns to opiate
administration.

Our lab is particularly interested in determining whether chronic opiate exposure
does indeed induce a functional switch to PFC-dependent neuronal encoding substrates,
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as I have proposed as a potential mechanism to explain the observed switch between a
D1-mediated versus D2-mediated (via pre-synaptically localized D2 receptors on
descending GLUT inputs to the BLA) opiate reward encoding mechanism within the
BLA. In addition, single unit recording studies of neurons within the BLA may help to
reveal more precisely how transmission via D1 versus D2 receptors may differentially
modulate neuronal population activity (e.g. intrinsic intemeuron versus projection neuron
populations) within the BLA.

Finally, future studies will incorporate molecular anatomical techniques such as
PCR and western blotting of BLA neural samples, to determine how opiate exposure state
may functionally regulate the expression levels of D1 versus D2 receptors directly within
the BLA. These studies, combined with the extensive series of behavioural studies
included in my thesis will hopefully reveal a clearer understanding of how the amygdala
encodes opiate addiction-related memories during the course of the opiate addiction
process.
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